{"id": "9Q6X14MAAAAJ", "citedby": 38145, "citedby5y": 11358, "hindex": 91, "hindex5y": 48, "i10index": 425, "i10index5y": 217, "coauthors": [], "name": "Mark Ratain", "affiliation": "Leon O. Jacobson Professor of Medicine, The University of Chicago", "interests": [], "cites_per_year": {"1987": 100, "1988": 93, "1989": 119, "1990": 188, "1991": 176, "1992": 198, "1993": 270, "1994": 305, "1995": 267, "1996": 265, "1997": 299, "1998": 427, "1999": 428, "2000": 598, "2001": 648, "2002": 744, "2003": 909, "2004": 868, "2005": 1117, "2006": 1519, "2007": 1693, "2008": 1732, "2009": 1740, "2010": 1829, "2011": 2196, "2012": 2416, "2013": 2544, "2014": 2505, "2015": 2361, "2016": 2259, "2017": 2131, "2018": 1838, "2019": 1921, "2020": 820}, "publications": [{"bib": {"title": "Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u5HHmVD_uO8C", "citedby": "4475"}, {"bib": {"title": "Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u-x6o8ySG0sC", "citedby": "1231"}, {"bib": {"title": "Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:d1gkVwhDpl0C", "citedby": "1015"}, {"bib": {"title": "Tumour heterogeneity in the clinic", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Y0pCki6q_DkC", "citedby": "777"}, {"bib": {"title": "UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9yKSN-GCB0IC", "citedby": "742"}, {"bib": {"title": "Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite \u2026", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2osOgNQ5qMEC", "citedby": "728"}, {"bib": {"title": "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qjMakFHDy7sC", "citedby": "722"}, {"bib": {"title": "Perceptions of cancer patients and their physicians involved in phase I trials.", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UeHWp8X0CEIC", "citedby": "574"}, {"bib": {"title": "Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IjCSPb-OGe4C", "citedby": "555"}, {"bib": {"title": "Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Tyk-4Ss8FVUC", "citedby": "473"}, {"bib": {"title": "Phenotype\u2010genotype correlation of in vitro SN\u201038 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zYLM7Y9cAGgC", "citedby": "402"}, {"bib": {"title": "Oral chemotherapy: rationale and future directions.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:W7OEmFMy1HYC", "citedby": "323"}, {"bib": {"title": "Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YsMSGLbcyi4C", "citedby": "292"}, {"bib": {"title": "Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eQOLeE2rZwMC", "citedby": "268"}, {"bib": {"title": "Pharmacogenomics: challenges and opportunities", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LkGwnXOMwfcC", "citedby": "262"}, {"bib": {"title": "The pharmacogenetics research network: from SNP discovery to clinical drug response", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_FxGoFyzp5QC", "citedby": "258"}, {"bib": {"title": "Phase I Trial of a Ligand Fusion-Protein (DAB389IL-2) in Lymphomas Expressing the Receptor for Interkeukin-2", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ufrVoPGSRksC", "citedby": "243"}, {"bib": {"title": "Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WF5omc3nYNoC", "citedby": "241"}, {"bib": {"title": "Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Se3iqnhoufwC", "citedby": "239"}, {"bib": {"title": "Rapamycin: something old, something new, sometimes borrowed and now renewed", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hqOjcs7Dif8C", "citedby": "231"}, {"bib": {"title": "Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0EnyYjriUFMC", "citedby": "229"}, {"bib": {"title": "Pharmacokinetic variability of anticancer agents", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7PzlFSSx8tAC", "citedby": "229"}, {"bib": {"title": "Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ULOm3_A8WrAC", "citedby": "224"}, {"bib": {"title": "Body surface area as a determinant of pharmacokinetics and drug dosing", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4TOpqqG69KYC", "citedby": "221"}, {"bib": {"title": "Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:roLk4NBRz8UC", "citedby": "220"}, {"bib": {"title": "Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8k81kl-MbHgC", "citedby": "219"}, {"bib": {"title": "Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:L8Ckcad2t8MC", "citedby": "218"}, {"bib": {"title": "Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UebtZRa9Y70C", "citedby": "211"}, {"bib": {"title": "Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5nxA0vEk-isC", "citedby": "206"}, {"bib": {"title": "Treatment of hairy cell leukemia with recombinant alpha 2 interferon", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MXK_kJrjxJIC", "citedby": "200"}, {"bib": {"title": "Anticancer drug discovery and development throughout the world", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KlAtU1dfN6UC", "citedby": "198"}, {"bib": {"title": "Measuring response in a post-RECIST world: from black and white to shades of grey", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aqlVkmm33-oC", "citedby": "196"}, {"bib": {"title": "Randomized discontinuation design: application to cytostatic antineoplastic agents", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3fE2CSJIrl8C", "citedby": "196"}, {"bib": {"title": "Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YOwf2qJgpHMC", "citedby": "196"}, {"bib": {"title": "Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kNdYIx-mwKoC", "citedby": "195"}, {"bib": {"title": "Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mVmsd5A6BfQC", "citedby": "193"}, {"bib": {"title": "A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Zph67rFs4hoC", "citedby": "193"}, {"bib": {"title": "Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_kc_bZDykSQC", "citedby": "185"}, {"bib": {"title": "A pharmacogenetic study of uridine diphosphate\u2013glucuronosyltransferase 2B7 in patients receiving morphine", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4DMP91E08xMC", "citedby": "183"}, {"bib": {"title": "Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QIV2ME_5wuYC", "citedby": "183"}, {"bib": {"title": "Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M3ejUd6NZC8C", "citedby": "176"}, {"bib": {"title": "Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Wp0gIr-vW9MC", "citedby": "174"}, {"bib": {"title": "Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non\u2013small-cell lung cancer", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9ZlFYXVOiuMC", "citedby": "173"}, {"bib": {"title": "Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-f6ydRqryjwC", "citedby": "171"}, {"bib": {"title": "Pharmacodynamics in cancer therapy.", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qxL8FJ1GzNcC", "citedby": "169"}, {"bib": {"title": "Cancer pharmacogenomics: strategies and challenges", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JV2RwH3_ST0C", "citedby": "167"}, {"bib": {"title": "The development of a financial toxicity patient\u2010reported outcome in cancer: the COST measure", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tKAzc9rXhukC", "citedby": "166"}, {"bib": {"title": "Pharmacogenetics and pharmacogenomics of anticancer agents", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:e5wmG9Sq2KIC", "citedby": "159"}, {"bib": {"title": "Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IWHjjKOFINEC", "citedby": "158"}, {"bib": {"title": "Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dhFuZR0502QC", "citedby": "154"}, {"bib": {"title": "Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:o9ULDYDKYbIC", "citedby": "149"}, {"bib": {"title": "A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:J_g5lzvAfSwC", "citedby": "149"}, {"bib": {"title": "Antitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qUcmZB5y_30C", "citedby": "147"}, {"bib": {"title": "Pharmacogenetics and cancer chemotherapy", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:R3hNpaxXUhUC", "citedby": "146"}, {"bib": {"title": "Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HDshCWvjkbEC", "citedby": "140"}, {"bib": {"title": "Preliminary antitumor activity of BAY 43\u20139006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZeXyd9-uunAC", "citedby": "137"}, {"bib": {"title": "Measuring financial toxicity as a clinically relevant patient\u2010reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0sTkTiv_uMkC", "citedby": "135"}, {"bib": {"title": "Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43\u20139006) in patients with advanced renal cell carcinoma (RCC)", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hC7cP41nSMkC", "citedby": "135"}, {"bib": {"title": "Quantitative analysis of ethical issues in phase I trials: a survey interview study of 144 advanced cancer patients", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hFOr9nPyWt4C", "citedby": "133"}, {"bib": {"title": "The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute \u2026", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:isC4tDSrTZIC", "citedby": "132"}, {"bib": {"title": "Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TQgYirikUcIC", "citedby": "132"}, {"bib": {"title": "Pharmacogenetics in cancer treatment", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mB3voiENLucC", "citedby": "130"}, {"bib": {"title": "Drug\u2010metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_Qo2XoVZTnwC", "citedby": "128"}, {"bib": {"title": "Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RHpTSmoSYBkC", "citedby": "128"}, {"bib": {"title": "Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:r0BpntZqJG4C", "citedby": "125"}, {"bib": {"title": "The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:xtRiw3GOFMkC", "citedby": "124"}, {"bib": {"title": "Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:j3f4tGmQtD8C", "citedby": "117"}, {"bib": {"title": "Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TFP_iSt0sucC", "citedby": "116"}, {"bib": {"title": "Clinical pharmacology of camptothecins", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bEWYMUwI8FkC", "citedby": "116"}, {"bib": {"title": "Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:iH-uZ7U-co4C", "citedby": "115"}, {"bib": {"title": "Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:fPk4N6BV_jEC", "citedby": "114"}, {"bib": {"title": "Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4JMBOYKVnBMC", "citedby": "112"}, {"bib": {"title": "Update on pharmacogenetics in cancer chemotherapy", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:maZDTaKrznsC", "citedby": "110"}, {"bib": {"title": "Optimising the design of phase II oncology trials: the importance of randomisation", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:blknAaTinKkC", "citedby": "109"}, {"bib": {"title": "Phase I\u2013II trial of erythropoietin in the treatment of cisplatin-associated anemia", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:k_IJM867U9cC", "citedby": "109"}, {"bib": {"title": "Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hMod-77fHWUC", "citedby": "108"}, {"bib": {"title": "Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u_35RYKgDlwC", "citedby": "106"}, {"bib": {"title": "Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M3NEmzRMIkIC", "citedby": "106"}, {"bib": {"title": "Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BqipwSGYUEgC", "citedby": "105"}, {"bib": {"title": "Paradoxical relationship between acetylator phenotype and amonafide toxicity", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:GnPB-g6toBAC", "citedby": "105"}, {"bib": {"title": "Camptothecin drug combinations and methods with reduced side effects", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YFjsv_pBGBYC", "citedby": "102"}, {"bib": {"title": "Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NMxIlDl6LWMC", "citedby": "101"}, {"bib": {"title": "Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RGFaLdJalmkC", "citedby": "98"}, {"bib": {"title": "Adoption of a clinical pharmacogenomics implementation program during outpatient care\u2013initial results of the University of Chicago \u201c1,200 Patients Project\u201d", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uWiczbcajpAC", "citedby": "97"}, {"bib": {"title": "SNP discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bFI3QPDXJZMC", "citedby": "95"}, {"bib": {"title": "Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ns9cj8rnVeAC", "citedby": "95"}, {"bib": {"title": "Pharmacokinetics and pharmacodynamics of long\u2010term continuous\u2010infusion doxorubicin", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RYcK_YlVTxYC", "citedby": "95"}, {"bib": {"title": "Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LjlpjdlvIbIC", "citedby": "94"}, {"bib": {"title": "The value meal: how to save $1,700 per month or more on lapatinib.", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:D03iK_w7-QYC", "citedby": "93"}, {"bib": {"title": "A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NaGl4SEjCO4C", "citedby": "92"}, {"bib": {"title": "A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3s1wT3WcHBgC", "citedby": "92"}, {"bib": {"title": "A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HoB7MX3m0LUC", "citedby": "91"}, {"bib": {"title": "Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:70eg2SAEIzsC", "citedby": "91"}, {"bib": {"title": "Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pqnbT2bcN3wC", "citedby": "91"}, {"bib": {"title": "The role of pharmacogenetics in cancer therapeutics", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ldfaerwXgEUC", "citedby": "90"}, {"bib": {"title": "Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:g5m5HwL7SMYC", "citedby": "90"}, {"bib": {"title": "Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lSLTfruPkqcC", "citedby": "90"}, {"bib": {"title": "TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SeFeTyx0c_EC", "citedby": "88"}, {"bib": {"title": "Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dfsIfKJdRG4C", "citedby": "88"}, {"bib": {"title": "Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yD5IFk8b50cC", "citedby": "88"}, {"bib": {"title": "Phase I clinical and pharmacokinetic study of protein kinase C-\u03b1 antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients \u2026", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:O3NaXMp0MMsC", "citedby": "87"}, {"bib": {"title": "Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rO6llkc54NcC", "citedby": "86"}, {"bib": {"title": "Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:35N4QoGY0k4C", "citedby": "86"}, {"bib": {"title": "Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M05iB0D1s5AC", "citedby": "86"}, {"bib": {"title": "The Role of SN\u201038 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:abG-DnoFyZgC", "citedby": "85"}, {"bib": {"title": "Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZHo1McVdvXMC", "citedby": "85"}, {"bib": {"title": "Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NnTm98qLMbgC", "citedby": "84"}, {"bib": {"title": "O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2P1L_qKh6hAC", "citedby": "84"}, {"bib": {"title": "Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4OULZ7Gr8RgC", "citedby": "84"}, {"bib": {"title": "Opportunities and challenges in the development of experimental drug combinations for cancer", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JoZmwDi-zQgC", "citedby": "83"}, {"bib": {"title": "CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pyW8ca7W8N0C", "citedby": "83"}, {"bib": {"title": "Development of target-based antineoplastic agents", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zA6iFVUQeVQC", "citedby": "82"}, {"bib": {"title": "Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CHSYGLWDkRkC", "citedby": "82"}, {"bib": {"title": "A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VOx2b1Wkg3QC", "citedby": "81"}, {"bib": {"title": "Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine\u2010kinase inhibitor", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:a0OBvERweLwC", "citedby": "81"}, {"bib": {"title": "Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bnK-pcrLprsC", "citedby": "81"}, {"bib": {"title": "A limited sampling strategy for cyclophosphamide pharmacokinetics", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vV6vV6tmYwMC", "citedby": "81"}, {"bib": {"title": "RECIST: no longer the sharpest tool in the oncology clinical trials toolbox\u2014point", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dQ2og3OwTAUC", "citedby": "80"}, {"bib": {"title": "Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor \u2026", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EUQCXRtRnyEC", "citedby": "80"}, {"bib": {"title": "A dosing/cross\u2010development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uWQEDVKXjbEC", "citedby": "78"}, {"bib": {"title": "Resistance to antimetabolites", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mJbmKSuM8toC", "citedby": "77"}, {"bib": {"title": "UGT pharmacogenomics: implications for cancer risk and cancer therapeutics", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:P5F9QuxV20EC", "citedby": "76"}, {"bib": {"title": "Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:f2IySw72cVMC", "citedby": "76"}, {"bib": {"title": "Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:b0M2c_1WBrUC", "citedby": "76"}, {"bib": {"title": "Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:D_sINldO8mEC", "citedby": "75"}, {"bib": {"title": "Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NhqRSupF_l8C", "citedby": "75"}, {"bib": {"title": "Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OU6Ihb5iCvQC", "citedby": "75"}, {"bib": {"title": "Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell \u2026", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UxriW0iASnsC", "citedby": "75"}, {"bib": {"title": "Limited sampling model for vinblastine pharmacokinetics", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cFHS6HbyZ2cC", "citedby": "75"}, {"bib": {"title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1taIhTC69MYC", "citedby": "74"}, {"bib": {"title": "Randomized phase II trials: a long-term investment with promising returns", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:q3oQSFYPqjQC", "citedby": "73"}, {"bib": {"title": "Pharmacogenomics: road to anticancer therapeutics nirvana?", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XiSMed-E-HIC", "citedby": "73"}, {"bib": {"title": "A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1sJd4Hv_s6UC", "citedby": "72"}, {"bib": {"title": "Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dshw04ExmUIC", "citedby": "72"}, {"bib": {"title": "A population model for the leukopenic effect of etoposide", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_xSYboBqXhAC", "citedby": "71"}, {"bib": {"title": "Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nb7KW1ujOQ8C", "citedby": "70"}, {"bib": {"title": "Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tS2w5q8j5-wC", "citedby": "70"}, {"bib": {"title": "Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4fKUyHm3Qg0C", "citedby": "69"}, {"bib": {"title": "Phase I study of amonafide dosing based on acetylator phenotype", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Tiz5es2fbqcC", "citedby": "69"}, {"bib": {"title": "In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UHK10RUVsp4C", "citedby": "68"}, {"bib": {"title": "Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:08ZZubdj9fEC", "citedby": "68"}, {"bib": {"title": "Weekly, high\u2010dose paclitaxel in advanced lung carcinoma: A Phase II study with pharmacokinetics by the Cancer and Leukemia Group B", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:738O_yMBCRsC", "citedby": "68"}, {"bib": {"title": "Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SP6oXDckpogC", "citedby": "67"}, {"bib": {"title": "Prognostic factors for survival in patients treated in phase I clinical trials", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KxtntwgDAa4C", "citedby": "67"}, {"bib": {"title": "Durability of responses to interferon alfa-2b in advanced hairy cell leukemia", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:l7t_Zn2s7bgC", "citedby": "67"}, {"bib": {"title": "Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uLbwQdceFCQC", "citedby": "66"}, {"bib": {"title": "Population pharmacokinetic model for irinotecan and two of its metabolites, SN\u201038 and SN\u201038 glucuronide", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wbdj-CoPYUoC", "citedby": "66"}, {"bib": {"title": "A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tOudhMTPpwUC", "citedby": "65"}, {"bib": {"title": "Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WbkHhVStYXYC", "citedby": "64"}, {"bib": {"title": "Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u9iWguZQMMsC", "citedby": "64"}, {"bib": {"title": "Limited sampling models for amonafide (NSC 308847) pharmacokinetics", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:p2g8aNsByqUC", "citedby": "64"}, {"bib": {"title": "Irinogenetics: what is the right star?", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LPZeul_q3PIC", "citedby": "63"}, {"bib": {"title": "Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5Ul4iDaHHb8C", "citedby": "63"}, {"bib": {"title": "Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ei5r6KrKXVQC", "citedby": "62"}, {"bib": {"title": "Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vRqMK49ujn8C", "citedby": "60"}, {"bib": {"title": "The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ufKn5pxu7C0C", "citedby": "59"}, {"bib": {"title": "Creating and evaluating genetic tests predictive of drug response", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:B3FOqHPlNUQC", "citedby": "58"}, {"bib": {"title": "In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8AbLer7MMksC", "citedby": "58"}, {"bib": {"title": "Irinotecan Dosing: Does the CPT in CPT-11 Stand for \u201cCan\u2019t Predict Toxicity\u201d?", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BrmTIyaxlBUC", "citedby": "58"}, {"bib": {"title": "Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JQOojiI6XY0C", "citedby": "57"}, {"bib": {"title": "Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia [see comments]", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kRWSkSYxWN8C", "citedby": "57"}, {"bib": {"title": "Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dTyEYWd-f8wC", "citedby": "56"}, {"bib": {"title": "\u201cIrinogenetics\u201d and UGT1A: from Genotypes to Haplotypes", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Y5dfb0dijaUC", "citedby": "56"}, {"bib": {"title": "Pharmacodynamics and long-term toxicity of etoposide", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Mojj43d5GZwC", "citedby": "56"}, {"bib": {"title": "Limited sampling models for doxorubicin pharmacokinetics.", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:fQNAKQ3IYiAC", "citedby": "55"}, {"bib": {"title": "Skeletal complications in hairy cell leukemia: diagnosis and therapy.", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WqliGbK-hY8C", "citedby": "55"}, {"bib": {"title": "Pharmacogenomics\u2010based point\u2010of\u2010care clinical decision support significantly alters drug prescribing", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cdwqcPQS8ssC", "citedby": "54"}, {"bib": {"title": "Phase II oncology trials: let's be positive", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:olpn-zPbct0C", "citedby": "54"}, {"bib": {"title": "Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5ugPr518TE4C", "citedby": "54"}, {"bib": {"title": "Modeling interpatient pharmacodynamic variability of etoposide", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:geHnlv5EZngC", "citedby": "54"}, {"bib": {"title": "The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:J-pR_7NvFogC", "citedby": "52"}, {"bib": {"title": "A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1yQoGdGgb4wC", "citedby": "52"}, {"bib": {"title": "Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and \u2026", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mvPsJ3kp5DgC", "citedby": "52"}, {"bib": {"title": "Pharmacogenetics", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sSrBHYA8nusC", "citedby": "52"}, {"bib": {"title": "Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eJXPG6dFmWUC", "citedby": "52"}, {"bib": {"title": "Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-FonjvnnhkoC", "citedby": "50"}, {"bib": {"title": "Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eq2jaN3J8jMC", "citedby": "50"}, {"bib": {"title": "5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9vf0nzSNQJEC", "citedby": "50"}, {"bib": {"title": "Modulation of vinblastine resistance with cyclosporine: a phase I study", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HE397vMXCloC", "citedby": "50"}, {"bib": {"title": "Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1qzjygNMrQYC", "citedby": "50"}, {"bib": {"title": "Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XiVPGOgt02cC", "citedby": "50"}, {"bib": {"title": "Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ehil0879vHcC", "citedby": "49"}, {"bib": {"title": "A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R (+) XK469 in patients with advanced solid tumours", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0KyAp5RtaNEC", "citedby": "49"}, {"bib": {"title": "A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:V3AGJWp-ZtQC", "citedby": "49"}, {"bib": {"title": "Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CRzUtm-VnGAC", "citedby": "48"}, {"bib": {"title": "Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EYYDruWGBe4C", "citedby": "48"}, {"bib": {"title": "Dose-escalation models for combination phase I trials in oncology", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PR6Y55bgFSsC", "citedby": "48"}, {"bib": {"title": "Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with \u2026", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BwyfMAYsbu0C", "citedby": "48"}, {"bib": {"title": "Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:t6usbXjVLHcC", "citedby": "48"}, {"bib": {"title": "A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:W5xh706n7nkC", "citedby": "48"}, {"bib": {"title": "Phase I Trial of Granulocyte\u2014Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B Study", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SdhP9T11ey4C", "citedby": "48"}, {"bib": {"title": "A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VL0QpB8kHFEC", "citedby": "48"}, {"bib": {"title": "Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-_dYPAW6P2MC", "citedby": "47"}, {"bib": {"title": "Study of cohort-specific consent and patient control in phase I cancer trials.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PELIpwtuRlgC", "citedby": "47"}, {"bib": {"title": "Granulocyte\u2010macrophage\u2010colony stimulating factor in metastatic renal cell carcinoma: A phase II trial", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AXPGKjj_ei8C", "citedby": "47"}, {"bib": {"title": "Phase I and pharmacological study of vinblastine by prolonged continuous infusion", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eMMeJKvmdy0C", "citedby": "47"}, {"bib": {"title": "Germline pharmacogenomics in oncology: decoding the patient for targeting therapy", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XD-gHx7UXLsC", "citedby": "46"}, {"bib": {"title": "Terminal ballistics of kinase inhibitors: there are no magic bullets", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_B80troHkn4C", "citedby": "46"}, {"bib": {"title": "Interpreting disparate responses to cancer therapy: the role of human population genetics", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NJ774b8OgUMC", "citedby": "46"}, {"bib": {"title": "Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7T2F9Uy0os0C", "citedby": "46"}, {"bib": {"title": "Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tkaPQYYpVKoC", "citedby": "46"}, {"bib": {"title": "Phase I study of adozelesin administered by 24-hour continuous intravenous infusion", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WA5NYHcadZ8C", "citedby": "46"}, {"bib": {"title": "Flushing oral oncology drugs down the toilet", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AvfA0Oy_GE0C", "citedby": "45"}, {"bib": {"title": "Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kzcrU_BdoSEC", "citedby": "45"}, {"bib": {"title": "Topoisomerase I inhibitors", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VLnqNzywnoUC", "citedby": "45"}, {"bib": {"title": "Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DJbcl8HfkQkC", "citedby": "44"}, {"bib": {"title": "Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lmc2jWPfTJgC", "citedby": "44"}, {"bib": {"title": "Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_Re3VWB3Y0AC", "citedby": "44"}, {"bib": {"title": "Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:t7zJ5fGR-2UC", "citedby": "44"}, {"bib": {"title": "Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vDijr-p_gm4C", "citedby": "44"}, {"bib": {"title": "Limited sampling model for area under the concentration time curve of total topotecan.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ye4kPcJQO24C", "citedby": "44"}, {"bib": {"title": "Analysis of the yield of phase II combination therapy trials in medical oncology", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Z5m8FVwuT1cC", "citedby": "43"}, {"bib": {"title": "A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:z_wVstp3MssC", "citedby": "43"}, {"bib": {"title": "Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network\u2014REFARGEN", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:edDO8Oi4QzsC", "citedby": "43"}, {"bib": {"title": "Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:N5tVd3kTz84C", "citedby": "43"}, {"bib": {"title": "Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZuybSZzF8UAC", "citedby": "43"}, {"bib": {"title": "Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5awf1xo2G04C", "citedby": "43"}, {"bib": {"title": "Design of phase i combination trials: recommendations of the clinical trial design task force of the nci investigational drug steering committee", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Aul-kAQHnToC", "citedby": "42"}, {"bib": {"title": "Evidence for clinical implementation of pharmacogenomics in cardiac drugs", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tH6gc1N1XXoC", "citedby": "41"}, {"bib": {"title": "Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non\u2013Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tYavs44e6CUC", "citedby": "41"}, {"bib": {"title": "Pharmacology of cancer chemotherapy", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eflP2zaiRacC", "citedby": "41"}, {"bib": {"title": "CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:FAceZFleit8C", "citedby": "40"}, {"bib": {"title": "Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8d8msizDQcsC", "citedby": "40"}, {"bib": {"title": "Pharmacogenomics and patient care: one size does not fit all", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BUYA1_V_uYcC", "citedby": "40"}, {"bib": {"title": "Recommended changes to oncology clinical trial design: revolution or evolution?", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:35r97b3x0nAC", "citedby": "40"}, {"bib": {"title": "From bedside to bench to bedside to clinical practice: an odyssey with irinotecan", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2KloaMYe4IUC", "citedby": "40"}, {"bib": {"title": "Learning from our patients: one participant's impact on clinical trial research and informed consent", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hkOj_22Ku90C", "citedby": "40"}, {"bib": {"title": "A genome-wide integrative study of microRNAs in human liver", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WJVC3Jt7v1AC", "citedby": "39"}, {"bib": {"title": "Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:URolC5Kub84C", "citedby": "39"}, {"bib": {"title": "Low-dose interferon alfa-2b in the treatment of hairy cell leukemia", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZfRJV9d4-WMC", "citedby": "39"}, {"bib": {"title": "Prognostic variables in hairy cell leukemia after splenectomy as initial therapy", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_Ybze24A_UAC", "citedby": "39"}, {"bib": {"title": "Etoposide pathway", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:GFxP56DSvIMC", "citedby": "38"}, {"bib": {"title": "A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and \u2026", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uJ-U7cs_P_0C", "citedby": "38"}, {"bib": {"title": "First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wMgC3FpKEyYC", "citedby": "37"}, {"bib": {"title": "Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nrtMV_XWKgEC", "citedby": "37"}, {"bib": {"title": "Pharmacogenetic pathway analysis of irinotecan", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:b1wdh0AR-JQC", "citedby": "37"}, {"bib": {"title": "Interpatient and intrapatient variability in vinblastine pharmacokinetics", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Fu2w8maKXqMC", "citedby": "37"}, {"bib": {"title": "Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ML0RJ9NH7IQC", "citedby": "36"}, {"bib": {"title": "Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hMsQuOkrut0C", "citedby": "36"}, {"bib": {"title": "Effects of green tea compounds on irinotecan metabolism", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MLfJN-KU85MC", "citedby": "36"}, {"bib": {"title": "Quality of life impact of three different doses of suramin in patients with metastatic hormone\u2010refractory prostate carcinoma: Results of Intergroup 0159/Cancer and Leukemia \u2026", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:p__nRnzSRKYC", "citedby": "36"}, {"bib": {"title": "Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:j8SEvjWlNXcC", "citedby": "36"}, {"bib": {"title": "A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:evX43VCCuoAC", "citedby": "36"}, {"bib": {"title": "Individualizing dosing of cancer chemotherapy", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tzM49s52ZIMC", "citedby": "36"}, {"bib": {"title": "Lack of association between common polymorphisms in UGT1A9 and gene expression and activity", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9Nmd_mFXekcC", "citedby": "35"}, {"bib": {"title": "Preparation and characterization of Pt direct deposition on polypyrrole modified Nafion composite membranes for direct methanol fuel cell applications", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:17ZO-CJnx_8C", "citedby": "35"}, {"bib": {"title": "Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4MWp96NkSFoC", "citedby": "35"}, {"bib": {"title": "Pharmacogenetics in cancer etiology and chemotherapy.", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ipzZ9siozwsC", "citedby": "35"}, {"bib": {"title": "Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:fEOibwPWpKIC", "citedby": "35"}, {"bib": {"title": "Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ILKRHgRFtOwC", "citedby": "34"}, {"bib": {"title": "Changes in Peripheral Blood and Bone Marrow Specimens Following Therapy with Recombinant Alpha2 Interferon for Hairy Cell Leukemia", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LI9QrySNdTsC", "citedby": "34"}, {"bib": {"title": "A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yB1At4FlUx8C", "citedby": "33"}, {"bib": {"title": "Pharmacology of 21-day oral etoposide given in combination with iv cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB \u2026", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:L7CI7m0gUJcC", "citedby": "33"}, {"bib": {"title": "Personalized medicine: building the GPS to take us there", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kz9GbA2Ns4gC", "citedby": "32"}, {"bib": {"title": "Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:gsN89kCJA0AC", "citedby": "32"}, {"bib": {"title": "Gazing into a crystal ball\u2013cancer therapy in the post-genomic era", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EkHepimYqZsC", "citedby": "32"}, {"bib": {"title": "Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:epqYDVWIO7EC", "citedby": "32"}, {"bib": {"title": "Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vbGhcppDl1QC", "citedby": "31"}, {"bib": {"title": "A phase I study of liposomal doxorubicin (Doxil) with topotecan", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M7yex6snE4oC", "citedby": "31"}, {"bib": {"title": "Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ALROH1vI_8AC", "citedby": "30"}, {"bib": {"title": "Pharmacogenomics: will the promise be fulfilled?", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HbR8gkJAVGIC", "citedby": "30"}, {"bib": {"title": "379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with \u2026", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zLWjf1WUPmwC", "citedby": "30"}, {"bib": {"title": "Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uc_IGeMz5qoC", "citedby": "30"}, {"bib": {"title": "Evaluation of neuropathy in patients on suramin treatment", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KUbvn5osdkgC", "citedby": "30"}, {"bib": {"title": "Mineralocorticoid insufficiency due to suramin therapy", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:k8Z6L05lTy4C", "citedby": "30"}, {"bib": {"title": "Bootstrap validation of pharmacodynamic models defined via stepwise linear regression", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oNZyr7d5Mn4C", "citedby": "30"}, {"bib": {"title": "The role of interferon in the treatment of hairy cell leukemia.", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4fGpz3EwCPoC", "citedby": "30"}, {"bib": {"title": "Cancer chemotherapy and skin changes", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:g3aElNc5_aQC", "citedby": "30"}, {"bib": {"title": "A phase I study of continuous infusion cilengitide in patients with solid tumors", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:anf4URPfarAC", "citedby": "29"}, {"bib": {"title": "Interpreting P values in pharmacogenetic studies: a call for process and perspective", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VaXvl8Fpj5cC", "citedby": "29"}, {"bib": {"title": "Clinical trial designs for cytostatic agents", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:S16KYo8Pm5AC", "citedby": "29"}, {"bib": {"title": "Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kuK5TVdYjLIC", "citedby": "29"}, {"bib": {"title": "Conservative management of primary cervical lymphoma using combination chemotherapy: a case report", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WZBGuue-350C", "citedby": "29"}, {"bib": {"title": "Methods for detection of promoter polymorphism in a UGT gene promoter", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QtA78RmWg5MC", "citedby": "28"}, {"bib": {"title": "Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck \u2026", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tuHXwOkdijsC", "citedby": "28"}, {"bib": {"title": "Analysis of impact of post-treatment biopsies in phase I clinical trials", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WC23djZS0W4C", "citedby": "27"}, {"bib": {"title": "Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0N-VGjzr574C", "citedby": "27"}, {"bib": {"title": "UGT1A1* 28 genotype affects the in-vitro glucuronidation of thyroxine in human livers", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_axFR9aDTf0C", "citedby": "27"}, {"bib": {"title": "Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:q3CdL3IzO_QC", "citedby": "27"}, {"bib": {"title": "Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:i2xiXl-TujoC", "citedby": "27"}, {"bib": {"title": "A Phase II trial of suramin monthly\u00d7 3 for hormone\u2010refractory prostate carcinoma", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rmuvC79q63oC", "citedby": "27"}, {"bib": {"title": "Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:xtoqd-5pKcoC", "citedby": "27"}, {"bib": {"title": "Insights into the pharmacokinetics and pharmacodynamics of irinotecan", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YohjEiUPhakC", "citedby": "27"}, {"bib": {"title": "Sequential treatment of hairy cell leukemia: a new role for interferon.", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TIZ-Mc8IlK0C", "citedby": "27"}, {"bib": {"title": "Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4e5Qn2KL_jwC", "citedby": "26"}, {"bib": {"title": "A pharmacogenetic study of vorinostat glucuronidation", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_5tno0g5mFcC", "citedby": "26"}, {"bib": {"title": "Testing the wrong hypothesis in phase II oncology trials: there is a better alternative", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ri6SYOTghG4C", "citedby": "26"}, {"bib": {"title": "Principles of cancer chemotherapy", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cWzG1nlazyYC", "citedby": "26"}, {"bib": {"title": "Methods for detection of promoter polymorphism in a UGT gene promoter", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:txeM2kYbVNMC", "citedby": "26"}, {"bib": {"title": "Phase I study to evaluate multiple regimens of intravenous 5\u2010fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a \u2026", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:e_rmSamDkqQC", "citedby": "26"}, {"bib": {"title": "Principles of antineoplastic drug development and pharmacology", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:P7Ujq4OLJYoC", "citedby": "26"}, {"bib": {"title": "Recent advances in the treatment of hairy-cell leukemia", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ug5p-4gJ2f0C", "citedby": "26"}, {"bib": {"title": "Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LhH-TYMQEocC", "citedby": "25"}, {"bib": {"title": "Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HeT0ZceujKMC", "citedby": "25"}, {"bib": {"title": "Biomarkers in early cancer drug development: limited utility", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XoXfffV-tXoC", "citedby": "25"}, {"bib": {"title": "Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SpbeaW3--B0C", "citedby": "25"}, {"bib": {"title": "Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5qfkUJPXOUwC", "citedby": "25"}, {"bib": {"title": "Hairy cell leukemia: current management", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kh2fBNsKQNwC", "citedby": "25"}, {"bib": {"title": "Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration\u2010resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB \u2026", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OBSaB-F7qqsC", "citedby": "24"}, {"bib": {"title": "UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6bLC7aUMtPcC", "citedby": "24"}, {"bib": {"title": "Resampling phase III data to assess phase II trial designs and endpoints", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NXb4pA-qfm4C", "citedby": "24"}, {"bib": {"title": "Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ruyezt5ZtCIC", "citedby": "24"}, {"bib": {"title": "Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DUooU5lO8OsC", "citedby": "24"}, {"bib": {"title": "A phase I study of subcutaneous recombinant interleukin\u20102 and interferon alfa\u20102a", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:86PQX7AUzd4C", "citedby": "24"}, {"bib": {"title": "Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4vMrXwiscB8C", "citedby": "24"}, {"bib": {"title": "Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kvJssbFybhEC", "citedby": "23"}, {"bib": {"title": "Targeted therapies: redefining the primary objective of phase I oncology trials", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PYBJJbyH-FwC", "citedby": "23"}, {"bib": {"title": "Conventional dosing of anticancer agents: precisely wrong or just inaccurate", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7H_MAutzIkAC", "citedby": "23"}, {"bib": {"title": "Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2tRrZ1ZAMYUC", "citedby": "23"}, {"bib": {"title": "The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:gVv57TyPmFsC", "citedby": "23"}, {"bib": {"title": "Value-based insurance design: aligning incentives, benefits, and evidence in oncology", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:fFSKOagxvKUC", "citedby": "23"}, {"bib": {"title": "Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:FPJr55Dyh1AC", "citedby": "23"}, {"bib": {"title": "Principles of pharmacokinetics and pharmacodynamics", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6ZxmRoH8BuwC", "citedby": "23"}, {"bib": {"title": "Interferon treatment for hairy cell leukemia: An update on a cohort of 69 patients treated from 1983-1986.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bz8QjSJIRt4C", "citedby": "23"}, {"bib": {"title": "Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:umqufdRvDiIC", "citedby": "23"}, {"bib": {"title": "Playing Russian roulette with tyrosine kinase inhibitors", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BJbdYPG6LGMC", "citedby": "22"}, {"bib": {"title": "A phase I study of sirolimus and bevacizumab in patients with advanced malignancies", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LO7wyVUgiFcC", "citedby": "22"}, {"bib": {"title": "Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Dip1O2bNi0gC", "citedby": "22"}, {"bib": {"title": "411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in \u2026", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9pM33mqn1YgC", "citedby": "22"}, {"bib": {"title": "Global gene expression as a function of germline genetic variation", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hCrLmN-GePgC", "citedby": "22"}, {"bib": {"title": "Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IUKN3-7HHlwC", "citedby": "22"}, {"bib": {"title": "Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ClCfbGk0d_YC", "citedby": "22"}, {"bib": {"title": "5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PoWvk5oyLR8C", "citedby": "22"}, {"bib": {"title": "Complete results from phase I dose escalation study of MetMAb, a monovalent antagonist antibody to the receptor met, dosed as single agent and in combination with bevacizumab \u2026", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0izLItjtcgwC", "citedby": "21"}, {"bib": {"title": "Principles of pharmacokinetics", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-nhnvRiOwuoC", "citedby": "21"}, {"bib": {"title": "Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PVjk1bu6vJQC", "citedby": "21"}, {"bib": {"title": "Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_FM0Bhl9EiAC", "citedby": "21"}, {"bib": {"title": "Laboratory and clinical studies of biochemical modulation by hydroxyurea.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mlAyqtXpCwEC", "citedby": "21"}, {"bib": {"title": "Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2VqYfGB8ITEC", "citedby": "21"}, {"bib": {"title": "Establishment of CYP2D6 reference samples by multiple validated genotyping platforms", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PVgj2kMGcgYC", "citedby": "20"}, {"bib": {"title": "New phase I trial methodology.", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:GtLg2Ama23sC", "citedby": "20"}, {"bib": {"title": "Simplifying the use of pharmacogenomics in clinical practice: building the genomic prescribing system", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:U5uP8zs9lfgC", "citedby": "19"}, {"bib": {"title": "Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:U_HPUtbDl20C", "citedby": "19"}, {"bib": {"title": "Meaningful use of pharmacogenetics", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:U4n9YNQMCAIC", "citedby": "19"}, {"bib": {"title": "Bar the windows but open the door to randomization", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yFnVuubrUp4C", "citedby": "19"}, {"bib": {"title": "The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KbBQZpvPDL4C", "citedby": "19"}, {"bib": {"title": "Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:r_AWSJRzSzQC", "citedby": "19"}, {"bib": {"title": "Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QYdC8u9Cj1oC", "citedby": "19"}, {"bib": {"title": "Therapeutic relevance of pharmacokinetics and pharmacodynamics.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HtEfBTGE9r8C", "citedby": "19"}, {"bib": {"title": "Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of pazopanib", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jFemdcug13IC", "citedby": "18"}, {"bib": {"title": "Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Bg7qf7VwUHIC", "citedby": "18"}, {"bib": {"title": "Models of excellence: improving oncology drug development", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OcBU2YAGkTUC", "citedby": "18"}, {"bib": {"title": "The UGT1A1\u2217 28 polymorphism correlates with erlotinib\u2019s effect on SN-38 glucuronidation", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_OXeSy2IsFwC", "citedby": "18"}, {"bib": {"title": "Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sNmaIFBj_lkC", "citedby": "18"}, {"bib": {"title": "Prescribing oral chemotherapy", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5MTHONV0fEkC", "citedby": "18"}, {"bib": {"title": "A phase I study of liposome-formulated cisplatin (SPI-77 (R)) given every 3 weeks in patients with advanced cancer", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XvxMoLDsR5gC", "citedby": "18"}, {"bib": {"title": "Pushing the envelope: Informed consent in phase I trials", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IRz6iEL74y4C", "citedby": "18"}, {"bib": {"title": "Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4hFrxpcac9AC", "citedby": "18"}, {"bib": {"title": "Experimental rationale for continuous infusion chemotherapy", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HIFyuExEbWQC", "citedby": "18"}, {"bib": {"title": "Time Is Money: Optimizing the Scheduling of Nivolumab.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KsTgnNRry18C", "citedby": "17"}, {"bib": {"title": "Patient perceptions of care as influenced by a large institutional pharmacogenomic implementation program", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:GJVTs2krol4C", "citedby": "17"}, {"bib": {"title": "The impact of industry on oncology research and practice", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XUvXOeBm_78C", "citedby": "17"}, {"bib": {"title": "Challenges in interpreting the evidence for genetic predictors of ototoxicity", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LgRImbQfgY4C", "citedby": "17"}, {"bib": {"title": "Vascular endothelial growth factor pathway", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0CzhzZyukY4C", "citedby": "17"}, {"bib": {"title": "Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OTTXONDVkokC", "citedby": "17"}, {"bib": {"title": "A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9c2xU6iGI7YC", "citedby": "17"}, {"bib": {"title": "ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PQEM9vzQD9gC", "citedby": "16"}, {"bib": {"title": "Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hsZV8lGYWTMC", "citedby": "16"}, {"bib": {"title": "Genome-wide interrogation of longitudinal FEV1 in children with asthma", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WAzi4Gm8nLoC", "citedby": "16"}, {"bib": {"title": "Forecasting unanticipated consequences of \u201cThe Sunshine Act\u201d: mostly cloudy", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4X0JR2_MtJMC", "citedby": "16"}, {"bib": {"title": "New feature: pathways and important genes from PharmGKB", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yMeIxYmEMEAC", "citedby": "16"}, {"bib": {"title": "Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ODE9OILHJdcC", "citedby": "16"}, {"bib": {"title": "Endostatin: are the 2 years up yet?", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8xutWZnSdmoC", "citedby": "16"}, {"bib": {"title": "Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1, 2-dithiole-3-thione (oltipraz) in patients with previously resected colon polyps and first-degree female relatives of \u2026", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mNrWkgRL2YcC", "citedby": "16"}, {"bib": {"title": "Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HtS1dXgVpQUC", "citedby": "16"}, {"bib": {"title": "Genetic predisposition to the metabolism of irinotecan (CPT-11)", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AHdEip9mkN0C", "citedby": "16"}, {"bib": {"title": "Disease\u2013drug database for pharmacogenomic\u2010based prescribing", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:c1AJUTjuCtUC", "citedby": "15"}, {"bib": {"title": "Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ce2CqMG-AY4C", "citedby": "15"}, {"bib": {"title": "Time to tumor growth: a model end point and new metric system for oncology clinical trials", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:otzGkya1bYkC", "citedby": "15"}, {"bib": {"title": "Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Dem6FJhTUoYC", "citedby": "15"}, {"bib": {"title": "Individualizing dosing of irinotecan", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:F1b5ZUV5XREC", "citedby": "15"}, {"bib": {"title": "Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yqoGN6RLRZoC", "citedby": "15"}, {"bib": {"title": "Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OP4eGU-M3BUC", "citedby": "15"}, {"bib": {"title": "A phase I study of intermittent infusion cladribine in patients with solid tumors", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dBIO0h50nwkC", "citedby": "15"}, {"bib": {"title": "Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MGPUR4WVBMEC", "citedby": "14"}, {"bib": {"title": "Uridine 5\u00b4-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7BrZ7Jt4UNcC", "citedby": "14"}, {"bib": {"title": "Exploring the relationship between polymorphic (TG/CA)nrepeats in intron 1 regions and gene expression", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:48xauSegjOkC", "citedby": "14"}, {"bib": {"title": "Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3htObqc8RwsC", "citedby": "14"}, {"bib": {"title": "Keratoacanthomas and skin neoplasms associated with suramin therapy", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vDZJ-YLwNdEC", "citedby": "14"}, {"bib": {"title": "Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:a3BOlSfXSfwC", "citedby": "14"}, {"bib": {"title": "Interferon alfa-2b antibodies and clinical resistance in a patient with hairy cell leukemia", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nZcligLrVowC", "citedby": "14"}, {"bib": {"title": "A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sfnaS5RM6jYC", "citedby": "13"}, {"bib": {"title": "The outlier in all of us: why implementing pharmacogenomics could matter for everyone", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:X5YyAB84Iw4C", "citedby": "13"}, {"bib": {"title": "Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:K3LRdlH-MEoC", "citedby": "13"}, {"bib": {"title": "Genome-wide identification of genetic determinants for the cytotoxicity of perifosine", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lvd772isFD0C", "citedby": "13"}, {"bib": {"title": "A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wKETBy42zhYC", "citedby": "13"}, {"bib": {"title": "A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bKqednn6t2AC", "citedby": "13"}, {"bib": {"title": "Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5icHVeHT4IsC", "citedby": "13"}, {"bib": {"title": "Optimization of cancer treatment with irinotecan", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7wO8s98CvbsC", "citedby": "13"}, {"bib": {"title": "Phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer.", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZzlSgRqYykMC", "citedby": "13"}, {"bib": {"title": "Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jE2MZjpN3IcC", "citedby": "13"}, {"bib": {"title": "Correspondence re: Raida, M. et al., Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5\u2032-Splice Donor Site of Intron 14 in \u2026", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:a9-T7VOCCH8C", "citedby": "13"}, {"bib": {"title": "Flavopiridol drug combinations and methods with reduced side effects", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pQTOvowfQioC", "citedby": "13"}, {"bib": {"title": "Schedules of 5-FU and the matrix metalloproteinase inhibitor marimastat: a phase I study", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u-coK7KVo8oC", "citedby": "13"}, {"bib": {"title": "Promising new agents in oncologic treatment.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NyGDZy8z5eUC", "citedby": "13"}, {"bib": {"title": "Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CdxZDUztZiMC", "citedby": "13"}, {"bib": {"title": "What is the choice of treatment for hairy cell leukemia?", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:43bX7VzcjpAC", "citedby": "13"}, {"bib": {"title": "Pharmacology", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZqLB7dQ1iF4C", "citedby": "12"}, {"bib": {"title": "User beware: We need more science and less art when measuring financial toxicity in oncology", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:w1MjKQ0l0TYC", "citedby": "12"}, {"bib": {"title": "Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jgBuDB5drN8C", "citedby": "12"}, {"bib": {"title": "Estimation of renal cell carcinoma treatment effects from disease progression modeling", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ak0FvsSvgGUC", "citedby": "12"}, {"bib": {"title": "Compositions and methods for treating pulmonary hypertension", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZqE1mSdD_DYC", "citedby": "12"}, {"bib": {"title": "Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CaZNVDsoPx4C", "citedby": "12"}, {"bib": {"title": "A phase I dose-escalation study of the safety and pharmacokinetics of XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nVrZBo8bIpAC", "citedby": "12"}, {"bib": {"title": "Pharmacodynamic modeling of prolonged administration of etoposide", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:F9fV5C73w3QC", "citedby": "12"}, {"bib": {"title": "New perspectives on the toxicity of etoposide.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:fbc8zXXH2BUC", "citedby": "12"}, {"bib": {"title": "Hairy cell leukaemia: the role of alpha interferon", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sJsF-0ZLhtgC", "citedby": "12"}, {"bib": {"title": "Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OR75R8vi5nAC", "citedby": "12"}, {"bib": {"title": "Flow cytometry in hairy cell leukemia before and during interferon alfa\u20102b therapy", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zCSUwVk65WsC", "citedby": "12"}, {"bib": {"title": "Food effect studies for oncology drug products", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CCeGMaHljPEC", "citedby": "11"}, {"bib": {"title": "When Less is More", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tFzHCjejgA0C", "citedby": "11"}, {"bib": {"title": "Comparative effects of CT imaging measurement on RECIST end points and tumor growth kinetics modeling", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SxCCDk4iOpsC", "citedby": "11"}, {"bib": {"title": "Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mUJArPsKIAAC", "citedby": "11"}, {"bib": {"title": "Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study \u2026", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MpfHP-DdYjUC", "citedby": "11"}, {"bib": {"title": "Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:L7vk9XBBNxgC", "citedby": "11"}, {"bib": {"title": "Pharmacogenomics of chemotherapeutic agents in cancer treatment", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3bvyWxjaHKcC", "citedby": "11"}, {"bib": {"title": "The treatment of hairy cell leukemia: an update.", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4xDN1ZYqzskC", "citedby": "11"}, {"bib": {"title": "Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:gKiMpY-AVTkC", "citedby": "11"}, {"bib": {"title": "Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:artPoR2Yc-kC", "citedby": "11"}, {"bib": {"title": "Glucuronidation of OTS167 in humans is catalyzed by UDP-glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KWzIFqRkAKkC", "citedby": "10"}, {"bib": {"title": "A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:F2UWTTQJPOcC", "citedby": "10"}, {"bib": {"title": "Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MhiOAD_qIWkC", "citedby": "10"}, {"bib": {"title": "Systemically administered drugs", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:buQ7SEKw-1sC", "citedby": "10"}, {"bib": {"title": "Outline of oncology therapeutics", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Br1UauaknNIC", "citedby": "10"}, {"bib": {"title": "Experimental rationale for continuous infusion chemotherapy", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1lhNe0rCu4AC", "citedby": "10"}, {"bib": {"title": "Genomic heterogeneity within individual prostate cancer foci impacts predictive biomarkers of targeted therapy", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vofGIMt6cyEC", "citedby": "9"}, {"bib": {"title": "Analyzing the clinical actionability of germline pharmacogenomic findings in oncology", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:GUYAmugLYisC", "citedby": "9"}, {"bib": {"title": "Providing balance in ASCO clinical practice guidelines: CYP2D6 genotyping and tamoxifen efficacy", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kJDgFkosVoMC", "citedby": "9"}, {"bib": {"title": "First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2v_ZtQDX9iAC", "citedby": "9"}, {"bib": {"title": "Unsupported off-label chemotherapy in metastatic colon cancer", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JTqpx9DYBaYC", "citedby": "9"}, {"bib": {"title": "A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ade32sEp0pkC", "citedby": "9"}, {"bib": {"title": "Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IaI1MmNe2tcC", "citedby": "9"}, {"bib": {"title": "DEVELOPMENT OF A PHARMACOKINETIC (PK) MODEL AND ASSESSMENT OF PATIENT (PT) COVARIATE EFFECTS ON DOSE-DEPENDENT PK FOLLOWING DIFFERENT DOSING SCHEDULES IN TWO PHASE I TRIALS OF \u2026", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6yz0xqPARnAC", "citedby": "9"}, {"bib": {"title": "A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:prdVHNxh-e8C", "citedby": "9"}, {"bib": {"title": "Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kVjdVfd2voEC", "citedby": "9"}, {"bib": {"title": "Sequential therapy with dacarbazine and carmustine: a phase I study", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lgwcVrK6X84C", "citedby": "9"}, {"bib": {"title": "Rapid response to 2\u2032\u2010deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AXkvAH5U_nMC", "citedby": "9"}, {"bib": {"title": "A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jU7OWUQzBzMC", "citedby": "9"}, {"bib": {"title": "Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-38epGy1wY0C", "citedby": "8"}, {"bib": {"title": "A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DrR-2ekChdkC", "citedby": "8"}, {"bib": {"title": "Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uVUOdF_882EC", "citedby": "8"}, {"bib": {"title": "A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LPtt_HFRSbwC", "citedby": "8"}, {"bib": {"title": "Value-based insurance design in oncology", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KaMxkj08jr0C", "citedby": "8"}, {"bib": {"title": "Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:FiytvqdAVhgC", "citedby": "8"}, {"bib": {"title": "Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LdasjJ6CEcoC", "citedby": "8"}, {"bib": {"title": "A genotype-directed phase I study of irinotecan in advanced cancer patients", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BzfGm06jWhQC", "citedby": "8"}, {"bib": {"title": "1249G>A polymorphism of ABCC2 (MRP2) is associated with altered gene expression in human liver", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cK4Rrx0J3m0C", "citedby": "8"}, {"bib": {"title": "Inside information: Financial conflicts of interest for research subjects in early phase clinical trials", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kw52XkFRtyQC", "citedby": "8"}, {"bib": {"title": "Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041)", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3NQIlFlcGxIC", "citedby": "8"}, {"bib": {"title": "Phase I study of an oral formulation of ZD9331 administered daily for 28 days", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PaBasH6fAo0C", "citedby": "8"}, {"bib": {"title": "A phase I study of suramin with once-or twice-monthly dosing in patients with advanced cancer", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WHdLCjDvYFkC", "citedby": "8"}, {"bib": {"title": "Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA)", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CB2v5VPnA5kC", "citedby": "8"}, {"bib": {"title": "Ethical issues in the clinical research of cancer", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ubry08Y2EpUC", "citedby": "8"}, {"bib": {"title": "Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456)", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rHJHxKgnXwkC", "citedby": "8"}, {"bib": {"title": "Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum (II) in patients with advanced cancer", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QD3KBmkZPeQC", "citedby": "8"}, {"bib": {"title": "Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single-and double-strand breaks, on a weekly\u00d7 2 every-3 \u2026", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SWgZeABleR0C", "citedby": "7"}, {"bib": {"title": "Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:65Yg0jNCQDAC", "citedby": "7"}, {"bib": {"title": "Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sszUF3NjhM4C", "citedby": "7"}, {"bib": {"title": "Are drug labels static or dynamic?", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:v1_lew4L6wgC", "citedby": "7"}, {"bib": {"title": "Final results from the phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with \u2026", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RoXSNcbkSzsC", "citedby": "7"}, {"bib": {"title": "A study of physician investigator (PI) disclosure of alternatives of care and prognostic information to advanced cancer patients (ACP) enrolling in phase I trials", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-jrNzM816MMC", "citedby": "7"}, {"bib": {"title": "A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yxmsSjX2EkcC", "citedby": "7"}, {"bib": {"title": "411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nRpfm8aw39MC", "citedby": "7"}, {"bib": {"title": "Camptothecin analogues: topotecan and irinotecan", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jL-93Qbq4QoC", "citedby": "7"}, {"bib": {"title": "Phase I trial of a diphtheria toxin (DT) fusion protein (DAB (389) IL-2) for the treatment of interleukin-2 receptor (IL-2R) expressing hematologic neoplasms.", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SjuI4pbJlxcC", "citedby": "7"}, {"bib": {"title": "Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7Hz3ACDFbsoC", "citedby": "7"}, {"bib": {"title": "Do patients with advanced cancer have the ability to make informed decisions for participation in phase I clinical trials?", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:h1pkognVyKwC", "citedby": "6"}, {"bib": {"title": "Intraindividual pharmacokinetic variability: focus on small\u2010molecule kinase inhibitors", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MNNNGtAgD4EC", "citedby": "6"}, {"bib": {"title": "Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network\u2010RIKEN (PGRN\u2010RIKEN) Collaboration", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TesyEGJKHF4C", "citedby": "6"}, {"bib": {"title": "Grading financial toxicity based upon its impact on health-related quality of life (HRQol).", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TaaCk18tZOkC", "citedby": "6"}, {"bib": {"title": "Institutional profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:isU91gLudPYC", "citedby": "6"}, {"bib": {"title": "brivanib (b) in advanced ovarian cancer (oc): subset results of a phase 2 randomized discontinuation trial (rdt)", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qSd0DAb9jMoC", "citedby": "6"}, {"bib": {"title": "Estimation of progression-free survival for all treated patients in the randomized discontinuation trial design", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CYCckWUYoCcC", "citedby": "6"}, {"bib": {"title": "Methods for detection of promoter polymorphism in a UGT gene promoter", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jKT558fuBk8C", "citedby": "6"}, {"bib": {"title": "Phase I study of rapamycin (R) in combination with CYP3A4 modifier, ketoconazole (K), in patients with advanced malignancies", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1Ye0OR6EYb4C", "citedby": "6"}, {"bib": {"title": "Pharmacogenomics of Deferiprone Metabolism.", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:owLR8QvbtFgC", "citedby": "6"}, {"bib": {"title": "Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NDuN12AVoxsC", "citedby": "6"}, {"bib": {"title": "Elimination pathways of [14C] losoxantrone in four cancer patients", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1yWc8FF-_SYC", "citedby": "6"}, {"bib": {"title": "A fixed-dose phase I study of ZD9331, a novel non-polyglutamated inhibitor of thymidylate synthase, in patients with refractory cancer", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MAUkC_7iAq8C", "citedby": "6"}, {"bib": {"title": "Drug combinations: Dangerous liaisons or great expectations?", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PyEswDtIyv0C", "citedby": "6"}, {"bib": {"title": "Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:L1USKYWJimsC", "citedby": "6"}, {"bib": {"title": "In vitro glucuronidation of flavopiridol (NSC649890)(FLAVO) by human liver microsomes", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-7ulzOJl1JYC", "citedby": "6"}, {"bib": {"title": "Phase I study to determine the effects of food on the absorption of oral 776C85 plus 5-fluorouracil in patients with advanced cancer", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-mN3Mh-tlDkC", "citedby": "6"}, {"bib": {"title": "Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:q-HalDI95KYC", "citedby": "6"}, {"bib": {"title": "Patient-provider communications about pharmacogenomic results increase patient recall of medication changes", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yKzB5RS27GgC", "citedby": "5"}, {"bib": {"title": "Interventional Pharmacoeconomics\u2014A New Discipline for a Cost-Constrained Environment", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DPO9WFcz7UcC", "citedby": "5"}, {"bib": {"title": "Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QAOzB4mb83kC", "citedby": "5"}, {"bib": {"title": "The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lRPiJ3GhvscC", "citedby": "5"}, {"bib": {"title": "Kinetic-pharmacodynamic model of chemotherapy-induced peripheral neuropathy in patients with metastatic breast cancer treated with paclitaxel, nab-paclitaxel, or ixabepilone \u2026", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:e3CVSTJ63dQC", "citedby": "5"}, {"bib": {"title": "In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AzKEL7Gb_04C", "citedby": "5"}, {"bib": {"title": "Preventing adverse drug-drug interactions: a need for improved data and logistics", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WC9gN4BGCRcC", "citedby": "5"}, {"bib": {"title": "Why RECIST Works and Why It Should Stay\u2014Reply to Counterpoint", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:An6A6Jpfc1oC", "citedby": "5"}, {"bib": {"title": "Importance of food effects for oral oncology drugs.", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dAp6zn-oMfAC", "citedby": "5"}, {"bib": {"title": "Financial burdens (FB), quality of life, and psychological distress among advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC).", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BrOSOlqYqPUC", "citedby": "5"}, {"bib": {"title": "The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Xl6nMSl579sC", "citedby": "5"}, {"bib": {"title": "Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC).", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:j7_hQOaDUrUC", "citedby": "5"}, {"bib": {"title": "Nonprofit biomedical companies", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qe6vwMD2xtsC", "citedby": "5"}, {"bib": {"title": "Problems with the randomized discontinuation design", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ehoypfNsBj8C", "citedby": "5"}, {"bib": {"title": "Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HGTzPopzzJcC", "citedby": "5"}, {"bib": {"title": "A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6_hjMsCP8ZoC", "citedby": "5"}, {"bib": {"title": "5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: A clinical and pharmacologic analysis", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:O0nohqN1r9EC", "citedby": "5"}, {"bib": {"title": "TREATMENT OF CHEMOTHERAPY INDUCED ANEMIA IN CANCER-PATIENTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Nw_I7GeUguwC", "citedby": "5"}, {"bib": {"title": "Correspondence re: MJ Egorin et al. Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with \u2026", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ziOE8S1-AIUC", "citedby": "5"}, {"bib": {"title": "LPG: A four-group probabilistic approach to leveraging pleiotropy in genome-wide association studies", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:onKP9CxGSkIC", "citedby": "4"}, {"bib": {"title": "A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ZYsTHYU9jrMC", "citedby": "4"}, {"bib": {"title": "Drug-drug interactions with oral antineoplastic agents", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rFyVMFCKTwsC", "citedby": "4"}, {"bib": {"title": "A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with \u2026", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1xBWf43XMUgC", "citedby": "4"}, {"bib": {"title": "Participation in cancer pharmacogenomic studies: a study of 8456 patients registered to clinical trials in the cancer and leukemia group B (alliance)", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Gpwnp1kGG20C", "citedby": "4"}, {"bib": {"title": "Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (A lliance)", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:gmHTDCtJMcoC", "citedby": "4"}, {"bib": {"title": "Vemurafenib oral bioavailability: an insoluble problem", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eO3_k5sD8BwC", "citedby": "4"}, {"bib": {"title": "Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients.", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:FiDNX6EVdGUC", "citedby": "4"}, {"bib": {"title": "Oncology micro-cap stocks: caveat emptor!", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nqdriD65xNoC", "citedby": "4"}, {"bib": {"title": "Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in \u2026", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rbm3iO8VlycC", "citedby": "4"}, {"bib": {"title": "Biomarkers and clinical care", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UuEBAcK4md4C", "citedby": "4"}, {"bib": {"title": "R (+) XK469 inhibits hydroxylation of S-warfarin by CYP2C9", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jSAVyFp_754C", "citedby": "4"}, {"bib": {"title": "The Werner\u2019s syndrome 4330T> C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pS0ncopqnHgC", "citedby": "4"}, {"bib": {"title": "Cellular transporter pharmacogenetics in metastatic colorectal cancer: initial analysis of C80203", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kzcSZmkxUKAC", "citedby": "4"}, {"bib": {"title": "Dyamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized, phase II trial", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:raTqNPD5sRQC", "citedby": "4"}, {"bib": {"title": "A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EPG8bYD4jVwC", "citedby": "4"}, {"bib": {"title": "Identification of a polymorphism in the UGT2B7 promoter: Association with morphine glucuronidation in patients.", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VN7nJs4JPk0C", "citedby": "4"}, {"bib": {"title": "Phase 1 study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kF1pexMAQbMC", "citedby": "4"}, {"bib": {"title": "High Variability in SN\u201038 Glucuronidation in Liver Samples from African Population as Predicted by UGT1A1 Genotypes", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KNjnJ3z-R6IC", "citedby": "4"}, {"bib": {"title": "Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase 1 (UGT1A1) gene", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pAkWuXOU-OoC", "citedby": "4"}, {"bib": {"title": "Genetic basis for the glucuronidation of SN-38: role of UGT* 1 isoform", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HJSXoJQnj-YC", "citedby": "4"}, {"bib": {"title": "Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte\u2010macrophage colony stimulating factor support", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YsrPvlHIBpEC", "citedby": "4"}, {"bib": {"title": "Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LXmCCkuhhTsC", "citedby": "4"}, {"bib": {"title": "A PROPOSAL FOR A NEW PHASE-I CLINICAL-TRIAL DESIGN-PATIENT CHOICE DOSE COHORT", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1DsIQWDZLl8C", "citedby": "4"}, {"bib": {"title": "Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oi2SiIJ9l4AC", "citedby": "4"}, {"bib": {"title": "Suramin: is adaptive control necessary?", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QsaTk4IG4EwC", "citedby": "4"}, {"bib": {"title": "Correspondence re: Xiu F. Hu et al., Combined Use of Cyclosporin A and Verapamil in Modulating Multidrug Resistance in Human Leukemia Cell Lines. Cancer Res., 50: 2953\u20132957, 1990", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9VeumLvkZSQC", "citedby": "4"}, {"bib": {"title": "A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:HhcuHIWmDEUC", "citedby": "4"}, {"bib": {"title": "Limited sampling models for amonafide pharmacokinetics", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DBa1UEJaJKAC", "citedby": "4"}, {"bib": {"title": "Periwinkle alkaloids I: vinblastine and vindesine", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YlPif8NxrbYC", "citedby": "4"}, {"bib": {"title": "Alternative dosing regimens for atezolizumab: right dose, wrong frequency", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sYWwZaPVD1oC", "citedby": "3"}, {"bib": {"title": "Ethical framework for including research biopsies in oncology clinical trials: american society of clinical oncology research statement", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:f2PrUAIjnKUC", "citedby": "3"}, {"bib": {"title": "A Pharmacogenetic Prediction Model of Progression\u2010Free Survival in Breast Cancer using Genome\u2010Wide Genotyping Data from CALGB 40502 (Alliance)", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jq04SsiGh3QC", "citedby": "3"}, {"bib": {"title": "Genetic variation determines VEGF-A plasma levels in cancer patients", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nroGzMJTTpEC", "citedby": "3"}, {"bib": {"title": "Potential for value-based prescribing of oral oncology drugs", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9CGX2owmTHMC", "citedby": "3"}, {"bib": {"title": "Taking a measured approach to toxicity data in phase I oncology clinical trials", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Wq2b2clWBLsC", "citedby": "3"}, {"bib": {"title": "Harmonization on renal function assessment is needed during early clinical development of oncology drugs", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eGYfIraVYiQC", "citedby": "3"}, {"bib": {"title": "Diarrhea", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Cvh0bltMcLgC", "citedby": "3"}, {"bib": {"title": "Might cigarettes be a \u201csmoking gun\u201d to reduce taxane myelotoxicity?", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mel-f30kHHgC", "citedby": "3"}, {"bib": {"title": "Reply to M. Todd et al", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SAZ1SQo2q1kC", "citedby": "3"}, {"bib": {"title": "434 First-in-man phase I study of PM01183 using an accelerated titration design", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2l5NCbZemmgC", "citedby": "3"}, {"bib": {"title": "Heritable interleukin-17F (IL17F) gene variation and overall survival (OS) in pancreatic cancer patients (pts): Results from a genome-wide association study (GWAS) in CALGB 80303", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zGdJYJv2LkUC", "citedby": "3"}, {"bib": {"title": "Grapefruit juice significantly increases bioavailability of weekly rapamycin (sirolimus)-evidence of safety and activity in a phase 1 study", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wkm4DBaukwsC", "citedby": "3"}, {"bib": {"title": "Intermittent dosing of Imetelstat Sodium, a telomerase inhibitor, induces drug exposure consistent with in vivo tumor growth inhibition", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1tZ8xJnm2c8C", "citedby": "3"}, {"bib": {"title": "Myelodysplastic syndromes: pathobiology and clinical management", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DquSII9TDu4C", "citedby": "3"}, {"bib": {"title": "A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:A8cqit5AE6sC", "citedby": "3"}, {"bib": {"title": "Polymorphisms in the Epidermal Growth Factor Receptor Gene Promoter", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:C-Rn0OCouf8C", "citedby": "3"}, {"bib": {"title": "Oral chemotherapy-Standardised dosing can improve the safety of prescribing", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Mx5hWS9ctUkC", "citedby": "3"}, {"bib": {"title": "A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic alpha nu ss 3 and alpha nu ss 5 integrin antagonist, in patients with advanced \u2026", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LK8CI43ZvvMC", "citedby": "3"}, {"bib": {"title": "Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:X9ykpCP0fEIC", "citedby": "3"}, {"bib": {"title": "A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic \u03b1v\u03b23 and \u03b1v\u03b25 integrin antagonist, in patients with advanced solid malignancy", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SnGPuo6Feq8C", "citedby": "3"}, {"bib": {"title": "A prospective pharmacogenomic (PG), pharmacodynamic (PD), and pharmacokinetic (PK) study of determinants of erlotinib toxicity", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rTD5ala9j4wC", "citedby": "3"}, {"bib": {"title": "Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kWvqk_afx_IC", "citedby": "3"}, {"bib": {"title": "Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QUX0mv85b1cC", "citedby": "3"}, {"bib": {"title": "382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-95Q15plzcUC", "citedby": "3"}, {"bib": {"title": "Finding the right dose.", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:69ZgNCALVd0C", "citedby": "3"}, {"bib": {"title": "General mechanisms of drug action", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:w0F2JDEymm0C", "citedby": "3"}, {"bib": {"title": "Delivery of a c-raf antisense oligodeoxynucleotide (LErafAON) by intermittent bolus dosing (weekly infusions) in patients with advanced solid tumors: a Phase I study", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:v_xunPV0uK0C", "citedby": "3"}, {"bib": {"title": "Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5 \u2026", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RVqaWcrwK10C", "citedby": "3"}, {"bib": {"title": "Cancer chemotherapy", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Xz60mAmATU4C", "citedby": "3"}, {"bib": {"title": "Glucuronidation of TAS-103: A novel anti-cancer agent", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aIdbFUkbNIkC", "citedby": "3"}, {"bib": {"title": "Single and multiple dose pharmacokinetics of SPI-77 (Stealth (R) liposomal cisplatin) given every 3 weeks in patients with advanced cancer", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Hck25ST_3aIC", "citedby": "3"}, {"bib": {"title": "Phase I study of 3\u2032-deamino-3\u2032-(2-methoxy-4-morpholinyl) doxorubicin (FCE 23762, PNU 152243) administered on a daily\u00d7 3 schedule", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PkcyUWeTMh0C", "citedby": "3"}, {"bib": {"title": "Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:k_7cPK9k7w8C", "citedby": "3"}, {"bib": {"title": "Dose reduction of etoposide in jaundiced patients.", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DkZNVXde3BIC", "citedby": "3"}, {"bib": {"title": "Hairy-cell leukemia", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IvSMUa3B7yYC", "citedby": "3"}, {"bib": {"title": "Clinical and genome-wide analysis of serum platinum levels after cisplatin-based chemotherapy", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LlXTz_FrCmAC", "citedby": "2"}, {"bib": {"title": "Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uWy0R8PweswC", "citedby": "2"}, {"bib": {"title": "A modeling and simulation study of less frequent dosing of nivolumab 480 mg.", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EsrhoZGmrkoC", "citedby": "2"}, {"bib": {"title": "Low-dose abiraterone with food: Rebutting an editorial", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:FQ36aI_S1AEC", "citedby": "2"}, {"bib": {"title": "The impact of sleep disturbances (SD) on quality of life, psychological morbidity, and survival of advanced cancer patients (ACP) and caregivers (CG).", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uoRD4RTSUPoC", "citedby": "2"}, {"bib": {"title": "Impact of the 2010 consensus recommendations of the clinical trial design task force of the NCI investigational drug steering committee", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oPLKW5k6eA4C", "citedby": "2"}, {"bib": {"title": "Redefining the primary objective of phase I oncology trials", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IT1MJ6E3JesC", "citedby": "2"}, {"bib": {"title": "Beneficial Effect of Adjuvant Chemotherapy and Whole Abdominal or Pelvic Radiotherapy (Waprt) on Progression Free and Overall Survival Following Primary Surgery in Patients \u2026", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:l6Q3WhenKVUC", "citedby": "2"}, {"bib": {"title": "Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TlpoogIpr_IC", "citedby": "2"}, {"bib": {"title": "A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QyXJ3EUuO1IC", "citedby": "2"}, {"bib": {"title": "A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:D_tqNUsBuKoC", "citedby": "2"}, {"bib": {"title": "Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S).", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eAlLMO4JVmQC", "citedby": "2"}, {"bib": {"title": "A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:silx2ntsSuwC", "citedby": "2"}, {"bib": {"title": "Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor Met, administered \u2026", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tHtfpZlB6tUC", "citedby": "2"}, {"bib": {"title": "Advances in drug development", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:v6i8RKmR8ToC", "citedby": "2"}, {"bib": {"title": "Abstract C169: intermittent dosing of Imetelstat Sodium, a telomerase inhibitor, induces drug exposure consistent with in vivo tumor growth inhibition", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8Xgff_V0N9gC", "citedby": "2"}, {"bib": {"title": "Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:T_ojBgVMvoEC", "citedby": "2"}, {"bib": {"title": "Clarification regarding \u201cphase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical \u2026", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DyXnQzXoVgIC", "citedby": "2"}, {"bib": {"title": "Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:__bU50VfleQC", "citedby": "2"}, {"bib": {"title": "Circadian variations in plasma 5-fluorouracil (5-FU) levels during 24-hour infusions", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AYInfyleIOsC", "citedby": "2"}, {"bib": {"title": "Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wE-fMHVdjMkC", "citedby": "2"}, {"bib": {"title": "Pharmacogenetics of flavopiridol, glucuronidation", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qE4H1tSSYIIC", "citedby": "2"}, {"bib": {"title": "Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-6RzNnnwWf8C", "citedby": "2"}, {"bib": {"title": "Two schedules of oral topotecan for myelodysplastic syndrome (MDS)-CALGB study 19803", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MIg0yeAD4ggC", "citedby": "2"}, {"bib": {"title": "Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UmS_249rOGwC", "citedby": "2"}, {"bib": {"title": "Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1A1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:C33y2ycGS3YC", "citedby": "2"}, {"bib": {"title": "A phase I trial of continuous infusion 5-fluorouracil and weekly gemcitabine: Updated results of an active combination for renal cell, hepatocellular and colon carcinoma", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:g5Ck-dwhA_QC", "citedby": "2"}, {"bib": {"title": "Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qwy9JoKyICEC", "citedby": "2"}, {"bib": {"title": "Etoposide combined with interferon alfa\u20102b: Novel exploitation of established etoposide pharmacokinetics and pharmacodynamics", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hSRAE-fF4OAC", "citedby": "2"}, {"bib": {"title": "Relationship Of CPT-11 induced diarrhea to glucuronidation of its metabolite SN-38", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:naSTrk-c4S8C", "citedby": "2"}, {"bib": {"title": "Evaluation of neuropathy in patients on suramin treatment", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:z6xuaG2dYH0C", "citedby": "2"}, {"bib": {"title": "PHASE-I STUDY OF 2-CHLORODEOXYADENOSINE IN HEMATOLOGIC MALIGNANCIES", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ghEM2AJqZyQC", "citedby": "2"}, {"bib": {"title": "PHASE-I TRIAL OF RECOMBINANT INTERLEUKIN-1-ALPHA (IL-1) AND RECOMBINANT INTERLEUKIN-2 (IL-2)", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zdjWy_NXXwUC", "citedby": "2"}, {"bib": {"title": "Rapid acetylators of amonafide (BIDA) have enhanced myelosuppression", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2ywjKiB__4kC", "citedby": "2"}, {"bib": {"title": "Low dose interferon alfa-2b for the induction of remission of hairy cell leukemia: A multi-institutional study of 49 patients", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:27LrP4qxOz0C", "citedby": "2"}, {"bib": {"title": "ADAPTIVE-CONTROL DOSING OF ETOPOSIDE (VP16)-A MEANS OF SAFELY INCREASING DOSE-INTENSITY", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wvYxNZNCP7wC", "citedby": "2"}, {"bib": {"title": "Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:w0odbtu79TwC", "citedby": "1"}, {"bib": {"title": "A Cost-Focused Alternative Cancer Medication Dispensing Strategy\u2014\u201cPack Splitting\u201d", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lPDSu1ZU3VAC", "citedby": "1"}, {"bib": {"title": "Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:10A3hb2jUxYC", "citedby": "1"}, {"bib": {"title": "Till death do us part: Existential loneliness (EL), psychosocial distress, and survival of advanced cancer patients (ACPs), and their spousal caregivers (SCs).", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PklR0melJeUC", "citedby": "1"}, {"bib": {"title": "The molecular profiling lottery: More accuracy, less precision, and no cost", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SPgmg5JLkoEC", "citedby": "1"}, {"bib": {"title": "Essential characteristics of pharmacogenomics study publications", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:koF6b02d8EEC", "citedby": "1"}, {"bib": {"title": "Fc\u2010gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO. 20 trial of metastatic colorectal cancer", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9tXw7Op4-u0C", "citedby": "1"}, {"bib": {"title": "Metabolism of megestrol acetate in vitro and the role of oxidative metabolites", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BCdnXsLIVDwC", "citedby": "1"}, {"bib": {"title": "Identification of a genomic region between SLC29A1 and HSP90AB1 associated with risk of bevacizumab-induced hypertension: CALGB 80405 (Alliance)", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jRIwE-1ttnoC", "citedby": "1"}, {"bib": {"title": "Safety and clinical activity of pembrolizumab immunotherapy and multi-organ site ablative stereotactic body radiotherapy (iMOSART) in patients with advanced solid tumors.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yCjxvIMm6_oC", "citedby": "1"}, {"bib": {"title": "A drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies.", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5rMqqAh47xYC", "citedby": "1"}, {"bib": {"title": "A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:J4E9jCG1tHUC", "citedby": "1"}, {"bib": {"title": "Obviating the Need for Serial Biopsies Through Random Assignment", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_tF6a-HnqWAC", "citedby": "1"}, {"bib": {"title": "Reply to TA Yap et al", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:c1e4I3QdEKYC", "citedby": "1"}, {"bib": {"title": "Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eFf2swCANGcC", "citedby": "1"}, {"bib": {"title": "A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC).", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vD2iS2Kej30C", "citedby": "1"}, {"bib": {"title": "A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hfzGNhXhx5MC", "citedby": "1"}, {"bib": {"title": "Analysis of impact of post-treatment biopsies in phase I clinical trials.", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:E8ajGqO0XoUC", "citedby": "1"}, {"bib": {"title": "A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3_LpOwP6eMYC", "citedby": "1"}, {"bib": {"title": "Prognostic information (PI), psychological well-being, and quality of life for advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC).", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hGdtkIFZdKAC", "citedby": "1"}, {"bib": {"title": "A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype.", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RuPIJ_LgqDgC", "citedby": "1"}, {"bib": {"title": "The development of a financial toxicity patient-reported outcome instrument (PRO) in cancer.", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RJOyoaXV5v8C", "citedby": "1"}, {"bib": {"title": "Physician\u2013investigator (PI) and patient communication regarding altruism and non-therapeutic benefits in phase I trials.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ji7lAbPyDbYC", "citedby": "1"}, {"bib": {"title": "An independent, external validation study of proposed genetic biomarkers of irinotecan toxicity and pharmacokinetics.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:37UQlXuwjP4C", "citedby": "1"}, {"bib": {"title": "Methods for predicting irinotecan toxicity", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JH5k92_tO-AC", "citedby": "1"}, {"bib": {"title": "VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QVtou7C4vgoC", "citedby": "1"}, {"bib": {"title": "Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:m4fbC6XIj1kC", "citedby": "1"}, {"bib": {"title": "A survey of the population genetic variation in the human kinome", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hQUaER0FWQ4C", "citedby": "1"}, {"bib": {"title": "Methods and compositions relating to the pharmacogenetics of different gene variants", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nPT8s1NX_-sC", "citedby": "1"}, {"bib": {"title": "In vitro glucuronidation of vorinostat", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:unp9ATQDT5gC", "citedby": "1"}, {"bib": {"title": "Addition of grapefruit juice (GJ) to increase the bioavailability of high-dose weekly rapamcyin (R)", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:c_xDhezhKKUC", "citedby": "1"}, {"bib": {"title": "A study of informed consent (IC), age, and cognitive performance (CP) among advanced cancer patients (acp) in phase I trials", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NxmKEeNBbOMC", "citedby": "1"}, {"bib": {"title": "The value meal: Effect of food on lapatinib Bioavailability-Reply", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PZE8UkGerEcC", "citedby": "1"}, {"bib": {"title": "Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:s85pQhAUCrAC", "citedby": "1"}, {"bib": {"title": "Effect of the Werner's syndrome gene variant 4330T> C on the cytotoxicity of camptothecin in lymphoblastoid cell lines", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:z8nqeaKD1nsC", "citedby": "1"}, {"bib": {"title": "Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4aZ_i-5WJEQC", "citedby": "1"}, {"bib": {"title": "Response to EGFR inhibitors in fibroblast cell lines and its association with germline polymorphisms", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:OzeSX8-yOCQC", "citedby": "1"}, {"bib": {"title": "A phase 1, dose-escalation trial of STA-5312, a microtubule inhibitor with a novel binding site, in advanced or metastatic solid malignancies", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:X0DADzN9RKwC", "citedby": "1"}, {"bib": {"title": "405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced \u2026", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:dhpJJ7xvgBgC", "citedby": "1"}, {"bib": {"title": "PTEN expression in archival tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ic1VZgkJnDsC", "citedby": "1"}, {"bib": {"title": "EGFR Pharmacogenomics", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:60iIaj97TE0C", "citedby": "1"}, {"bib": {"title": "A PHARMACOGENETIC STUDY OF ALDEHYDE OXIDASE IN PATIENTS TREATED WITH R (+) XK469", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u_mOZUIutIEC", "citedby": "1"}, {"bib": {"title": "A dose-escalation study of the quinoxaline antitumor agent R (+) XK469 (XK) in patients with refractory solid tumors", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BmWJbWwHJAwC", "citedby": "1"}, {"bib": {"title": "The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in Caucasian and African American patients with solid tumors", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JP7YXuLIOvAC", "citedby": "1"}, {"bib": {"title": "Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-yGd096yOn8C", "citedby": "1"}, {"bib": {"title": "Green tea and irinotecan metabolism", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wLxue7F8ec0C", "citedby": "1"}, {"bib": {"title": "In vitro glucuronidation of ABT\u2010751, a novel anticancer agent", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YTuZlYwrTOUC", "citedby": "1"}, {"bib": {"title": "Endostatin: Are the 2 Years Up Yet?", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WMtz-WDmgKQC", "citedby": "1"}, {"bib": {"title": "Welcome to the pharmacogenomics journal", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NtGNdKbuCngC", "citedby": "1"}, {"bib": {"title": "A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8dzOF9BpDQoC", "citedby": "1"}, {"bib": {"title": "CORRELATION OF UGT1A1 GENOTYPE VERSUS SN-38 AND BILIRUBIN GLUCURONIDATION IN HUMAN LIVER SAMPLES", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ijdKiLOsEJMC", "citedby": "1"}, {"bib": {"title": "Population pharmacokinetic determination of the effect of food on the pharmacokinetics of oral 5-fluorouracil (FU) and eniluracil (776C85, 776)", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:t-hv7AR41mYC", "citedby": "1"}, {"bib": {"title": "Phase I study of ZD9331 using a 5-day short infusion schedule", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:s9ia6_kGH2AC", "citedby": "1"}, {"bib": {"title": "Phase I study of CEP-2563 dihydrochloride (CEP-2563), a tyrosine kinase inhibitor, in patients with solid tumors", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:G1UMdFYMoxkC", "citedby": "1"}, {"bib": {"title": "Plasma 2'-deoxyuridine (dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in patients in phase I clinical trials of the TS inhibitor ZD9331", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-uzm3Y7AvW0C", "citedby": "1"}, {"bib": {"title": "Phase I study of a novel DPD inhibitor GW776C85 and oral 5-FU with RT in recurrent or advanced head and neck cancer", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0aBXIfxlw9sC", "citedby": "1"}, {"bib": {"title": "Rationale for phase I study of UFT plus leucovorin and oral JM-216", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7H_jS4BsgvYC", "citedby": "1"}, {"bib": {"title": "Pharmacokinetic\u2010pharmacodynamic (PK\u2010PD) analysis of intestinal toxicity associated with irinotecan (CPT\u201011): validation of biliary index (BI)", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jmjb1lOE9QIC", "citedby": "1"}, {"bib": {"title": "A population pharmacokinetic study of suramin (SUR) by intermittent infusion in patients with advanced cancer (CA)", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JWITY9-sCbMC", "citedby": "1"}, {"bib": {"title": "A population-model for the leukopenic effect of etoposide", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hvmnpdAuIbkC", "citedby": "1"}, {"bib": {"title": "Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BJrgspguQaEC", "citedby": "1"}, {"bib": {"title": "INDIVIDUALIZED DOSING OF AMONAFIDE (BIDA)", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:zUl2_INMlC4C", "citedby": "1"}, {"bib": {"title": "A PHASE-I STUDY OF 2-CHLORODEOXYADENOSINE (2-CDA) IN SOLID TUMORS", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CNPyR2KL9-0C", "citedby": "1"}, {"bib": {"title": "A PHASE-I COHORT STUDY OF SURAMIN IN PATIENTS WITH ADVANCED CANCER", "year": "1992"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:c59VksA5Vz4C", "citedby": "1"}, {"bib": {"title": "INDIVIDUALIZED DOSING OF ETOPOSIDE (VP16)-A POSSIBLE MEANS OF INCREASING DOSE-INTENSITY", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LGlY6t8CeOMC", "citedby": "1"}, {"bib": {"title": "Correspondence re: Mark J. Ratain et al., Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics. Cancer Res., 48: 4127\u20134130, 1988\u2014Reply", "year": "1989"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:-DxkuPiZhfEC", "citedby": "1"}, {"bib": {"title": "PHASE-I AND INVITRO STUDIES OF HYDROXYUREA AND ETOPOSIDE", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:xyvS_IvSCKsC", "citedby": "1"}, {"bib": {"title": "INTRAPATIENT AND INTERPATIENT VARIABILITY IN PHARMACOKINETICS OF HIGH-DOSE ORAL MELPHALAN", "year": "1988"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EsEWqaRxkBgC", "citedby": "1"}, {"bib": {"title": "PHARMACOKINETIC STUDY OF HIGH-DOSE ORAL MELPHALAN", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:H_jBuBxbQIAC", "citedby": "1"}, {"bib": {"title": "INCREASED RISK OF ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL) FOLLOWING CISPLATIN (DDP), ETOPOSIDE (VP), VINDESINE (VDS) THERAPY FOR ADVANCED NON-SMALL CELL LUNG-CANCER (NSCLC)", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sA9dB-pw3HoC", "citedby": "1"}, {"bib": {"title": "Use in Hairy Cell Leukemia. An Update", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lYAcb2jw7qUC", "citedby": "1"}, {"bib": {"title": "VENTILATION-PERFUSION SCANS MAY DETECT EARLY INVASIVE PULMONARY ASPERGILLOSIS", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_AeoHAGD03cC", "citedby": "1"}, {"bib": {"title": "PHASE-I PHARMACOKINETIC (PK) AND TOXICITY STUDY OF PROLONGED CONTINUOUS INFUSION VINBLASTINE (CIV) USING INFUSION (INF) PUMPS", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RtRctb2lSbAC", "citedby": "1"}, {"bib": {"title": "Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumors", "year": "23"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3lUAU8Oskd0C", "citedby": "1"}, {"bib": {"title": "Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8O4vDxvErlEC", "citedby": "0"}, {"bib": {"title": "Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:T_0gP6tLVL0C", "citedby": "0"}, {"bib": {"title": "Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:J6OZcwVsj5AC", "citedby": "0"}, {"bib": {"title": "Talking the talk about tumor genomic testing", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sfsSB7lKuh0C", "citedby": "0"}, {"bib": {"title": "Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qhW0HyKmSusC", "citedby": "0"}, {"bib": {"title": "Personalized Management of Chemotherapy\u2010Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:09LM3QYkMKUC", "citedby": "0"}, {"bib": {"title": "Pharmacogenomic\u2010Based Decision\u2010Support to Predict Adherence to Medications", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:xlVdBZVQT58C", "citedby": "0"}, {"bib": {"title": "BASELINE KNOWLEDGE, PERCEPTIONS, AND BARRIERS OF PHARMACOGENOMIC (PGX) IMPLEMENTATION IN THE PERIOPERATIVE (P/O) SETTING.", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vkuYBMKU6wEC", "citedby": "0"}, {"bib": {"title": "EVALUATING RACIAL POPULATION (POP) SPECIFIC RISK FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) GUIDANCE.", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DwWRdx-KAo4C", "citedby": "0"}, {"bib": {"title": "POTENTIAL IMPACT OF PHARMACOGENOMIC (PGX) TESTING IN ONCOLOGY PATIENTS.", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:anDooRL1HQEC", "citedby": "0"}, {"bib": {"title": "PATIENT (PT) EDUCATION ABOUT PHARMACOGENOMICS (PGX) TO ENHANCE PERSONALIZED PRESCRIBING (PEPEPP).", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bkKuixW_xMkC", "citedby": "0"}, {"bib": {"title": "Genome-Wide Meta-Analysis Identifies a S1PR1 Genomic Region Associated with Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qYOp8iumCsAC", "citedby": "0"}, {"bib": {"title": "Assessment of patient knowledge and perceptions of pharmacogenomics before and after using a mock results patient web portal", "year": "2020"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Oo_WeVVXg5wC", "citedby": "0"}, {"bib": {"title": "A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex \u2026", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lSLsV1MU4ZUC", "citedby": "0"}, {"bib": {"title": "A new liver eQTL map from 1,183 individuals provides evidence for novel eQTLs of drug response, metabolic and sex\u2010biased phenotypes", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RJujIP1NYNUC", "citedby": "0"}, {"bib": {"title": "The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_n8fIOMweQoC", "citedby": "0"}, {"bib": {"title": "Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MqTxh1vmwXEC", "citedby": "0"}, {"bib": {"title": "First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JIEWM9yDoCIC", "citedby": "0"}, {"bib": {"title": "Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aU4yMueWZ3QC", "citedby": "0"}, {"bib": {"title": "Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Lo8V22OuN40C", "citedby": "0"}, {"bib": {"title": "An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qbqt7gslDFUC", "citedby": "0"}, {"bib": {"title": "From pharmacogenomics testing to point-of-care clinical decision support", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tSVUDDkujAIC", "citedby": "0"}, {"bib": {"title": "Pharmacogenomic considerations for medications in the perioperative setting", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aCwMkEyfDy8C", "citedby": "0"}, {"bib": {"title": "Pharmacokinetic modeling of serum platinum reveals extent of long-term exposure and associated comorbidities after cisplatin treatment", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cx97FdCJQX8C", "citedby": "0"}, {"bib": {"title": "Precision and Accuracy in the Brave New World of Basket Trials", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oYwriLWYh5YC", "citedby": "0"}, {"bib": {"title": "The Role of Early-Phase Design", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:e9bUPLv0EjcC", "citedby": "0"}, {"bib": {"title": "Two Polymorphic Gene Loci Associated with Treprostinil Dose in Pulmonary Arterial Hypertension", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Yw6v6SrDvuUC", "citedby": "0"}, {"bib": {"title": "THE IMPACT OF PHARMACOGENOMICS ON MEDICATION ADHERENCE.", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:k8to_Y4Q4_EC", "citedby": "0"}, {"bib": {"title": "DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE WARFARIN PHARMACOGENOMICS PANEL IN CLINICAL PRACTICE: AN ACCOUNT CONSORTIUM STUDY.", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:e0LTWoPxLYMC", "citedby": "0"}, {"bib": {"title": "PHARMACOGENOMIC EVIDENCE FOR CLINICAL IMPLEMENTATION WITHIN RHEUMATOLOGY.", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bbjcffOLshcC", "citedby": "0"}, {"bib": {"title": "DEVELOPMENT OF A PATIENT PORTAL TO DELIVER PHARMACOGENOMICS RESULTS TO PATIENTS.", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SgM-ki2adj0C", "citedby": "0"}, {"bib": {"title": "Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ovGv7akYl-cC", "citedby": "0"}, {"bib": {"title": "Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:r56sNq9gaawC", "citedby": "0"}, {"bib": {"title": "Acknowledgement of Reviewers 2018", "year": "2019"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JqN3CTdJtl0C", "citedby": "0"}, {"bib": {"title": "Reply to IF Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and FJSH Woei-A-Jin et al", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oFn-K-OQSCAC", "citedby": "0"}, {"bib": {"title": "In Sickness and Health: Loneliness (LS), Psychological Well-being, and Survival of Advanced Cancer Patients (ACP) In Phase I Trials and Their Spousal Caregivers (SC)", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QeguYG95ZbAC", "citedby": "0"}, {"bib": {"title": "1556O Potential for value-based prescribing of oral oncology drugs", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IExZWSxeYXUC", "citedby": "0"}, {"bib": {"title": "1868P A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3_f9JqYsqVQC", "citedby": "0"}, {"bib": {"title": "Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:w7CBUyPWg-0C", "citedby": "0"}, {"bib": {"title": "PHARMACOGENOMIC EVIDENCE IN PERIOPERATIVE DRUGS FOR CLINICAL IMPLEMENTATION.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1paMEeroeoQC", "citedby": "0"}, {"bib": {"title": "EVALUATING THE POTENTIAL RELEVANCE OF PHARMACOGENOMIC INFORMATION FOR MEDICATIONS ADMINISTERED TO SURGICAL PATIENTS.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RJNGbXJAtMsC", "citedby": "0"}, {"bib": {"title": "DISCOVERY OF SNPS ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY USING MODEL ESTIMATED PARAMETERS AS PHENOTYPES.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pxXbYLTb8EgC", "citedby": "0"}, {"bib": {"title": "CHANGES IN PROVIDER KNOWLEDGE AND PERCEPTIONS OF PHARMACOGENOMICS AFTER PARTICIPATION IN AN INSTITUTIONAL IMPLEMENTATION STUDY.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TiIbgCYny7sC", "citedby": "0"}, {"bib": {"title": "IMPACT OF PREEMPTIVE CYP2D6 GENOTYPING: RESULTS FROM AN INSTITUTIONAL PHARMACOGENOMICS PROGRAM.", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bCjgOgSFrM0C", "citedby": "0"}, {"bib": {"title": "The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial \u2026", "year": "2018"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:j7XjBeKFbTsC", "citedby": "0"}, {"bib": {"title": "The impact of death anxiety (DA) on the psychological morbidity, health-related quality of life, and survival for advanced cancer patients (ACP) in phase I trials and their \u2026", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4E1Y8I9HL1wC", "citedby": "0"}, {"bib": {"title": "Drug-Drug Interactions With Oral Antineoplastic Agents (vol 3, pg 736, 2016)", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:UKB2i6g6GNMC", "citedby": "0"}, {"bib": {"title": "Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib.", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hEXC_dOfxuUC", "citedby": "0"}, {"bib": {"title": "ANALYSIS OF ADULT IN-HOSPITAL MEDICATIONS FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) INFORMATION.", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oynPyU19kbsC", "citedby": "0"}, {"bib": {"title": "POINT-OF-CARE PROVIDER USE OF PHARMACOGENOMIC (PGX) RESULTS DURING PRESCRIBING IMPACTS PATIENT (PT) RECALL OF MEDICATION RECOMMENDATIONS", "year": "2017"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XtJa11BXPS4C", "citedby": "0"}, {"bib": {"title": "Identification of clinically actionable drug-drug-gene interactions that impact pharmacogenomic prescribing: 247.", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NZNkWSpQBv0C", "citedby": "0"}, {"bib": {"title": "Influence of N-acetyltransferase 2 (NAT2) gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Nnq8S6OXqDYC", "citedby": "0"}, {"bib": {"title": "Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3x-KLxxGyuUC", "citedby": "0"}, {"bib": {"title": "Genomic prescribing system and methods", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:E7VqQtBCVmcC", "citedby": "0"}, {"bib": {"title": "A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate \u2026", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_mQi-xiA4oYC", "citedby": "0"}, {"bib": {"title": "CLINICAL DECISION SUPPORTS (CDS) TO INCORPORATE PHARMACOGENOMICS (PGx) INTO DECISION MAKING IN PERIOPERATIVE CARE.: PII-003", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ojlX30-wUrgC", "citedby": "0"}, {"bib": {"title": "BIOMARKER OUTCOMES IN EARLY PHASE ONCOLOGY TRIALS INCLUDING NON-DIAGNOSTIC BIOPSIES.: PII-031", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oYLFIHfuHKwC", "citedby": "0"}, {"bib": {"title": "ANALYSIS OF CLINICALLY ACTIONABLE PREEMPTIVE PHARMACOGENOMIC (PGx) INFORMATION TO IMPACT IN-HOSPITAL PRESCRIBING.: OIII-4", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cRMvf6lLvU8C", "citedby": "0"}, {"bib": {"title": "Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RXiHnyRawswC", "citedby": "0"}, {"bib": {"title": "PATIENT (PT) PERCEPTIONS OF CARE AS INFLUENCED BY THE IMPLEMENTATION OF A LARGE INSTITUTIONAL PHARMACOGENOMIC TESTING PROGRAM.: PT-19", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tz746QTLzJkC", "citedby": "0"}, {"bib": {"title": "IMPLEMENTATION OF HIGHLY CHARACTERIZED CYP2D6 GENOTYPES WITH COPY NUMBER ASSESSMENT: RESULTS OF A PREEMPTIVE INSTITUTIONAL PHARMACOGENOMIC (PGX) TESTING PROGRAM.: PII-039", "year": "2016"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eI34FqJmdUoC", "citedby": "0"}, {"bib": {"title": "655: A PILOT STUDY FOR CLINICAL IMPLEMENTATION OF PHARMACOGENOMICS (PGX) IN PERIOPERATIVE CARE", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6ZzL7HXColQC", "citedby": "0"}, {"bib": {"title": "PI-REAL: A study of informed consent (IC) communication in real-time during phase I clinical trial encounters.", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QaSi33NTfwYC", "citedby": "0"}, {"bib": {"title": "Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC).", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eAUscmXIlQ8C", "citedby": "0"}, {"bib": {"title": "ABC TRANSPORTER POLYMORPHISMS ARE ASSOCIATED WITH IRINOTECAN EXPOSURE AND NEUTROPENIA: PII-022", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:inmFHauC9wsC", "citedby": "0"}, {"bib": {"title": "ANALYZING THE CLINICAL ACTIONABILITY OF GERMLINE PHARMACOGENOMIC (PGX) DATA IN ONCOLOGY (ONC): PI-039", "year": "2015"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:i_7YvbSbtFEC", "citedby": "0"}, {"bib": {"title": "66 Clinical validity of new genetic biomarkers of irinotecan neutropenia: An independent replication study", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sJK75vZXtG0C", "citedby": "0"}, {"bib": {"title": "A Model-Based Approach to Dose Optimization of Neurotoxic Chemotherapy Drugs", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oAywNP-vUhwC", "citedby": "0"}, {"bib": {"title": "Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE)", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:2vr6o8x5NLkC", "citedby": "0"}, {"bib": {"title": "180P GENOME-WIDE ASSOCIATION STUDY (GWAS) IDENTIFIES CANDIDATE NEUROTOXICITY MARKERS IN PLATINUM-TAXANE TREATED OVARIAN CANCER PATIENTS IN ICON7", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3BvdIg-l-ZAC", "citedby": "0"}, {"bib": {"title": "Marital distress (MD), quality of life, and psychological morbidity among advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC).", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:X4-KO54GjGYC", "citedby": "0"}, {"bib": {"title": "Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yTLRzDEmwhEC", "citedby": "0"}, {"bib": {"title": "A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:L24QuVWYgZ0C", "citedby": "0"}, {"bib": {"title": "ESTABLISHMENT OF CYP2D6 REFERENCE SAMPLES BY MULTIPLE VALIDATED GENOTYPING PLATFORMS.: PI-027", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_AkkBXT-jcoC", "citedby": "0"}, {"bib": {"title": "MEGESTROL ACETATE GLUCURONIDATION.: PII-031", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:adHtZc2wMuEC", "citedby": "0"}, {"bib": {"title": "METABOLISM OF MEGESTROL ACETATE IN VITRO AND THE ROLE OF OXIDATIVE METABOLITES.: PI-032", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8RAEygVn5_EC", "citedby": "0"}, {"bib": {"title": "IN VITRO GLUCURONIDATION OF OTS167.: PII-037", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yIeBiWEAh44C", "citedby": "0"}, {"bib": {"title": "CLINICAL IMPACT OF AN ON-DEMAND GENOMIC PRESCRIBING SYSTEM (GPS) FOR PHARMACOGENOMIC (PGx) RESULTS DELIVERY.: PT-021", "year": "2014"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RMgMIBzvq-4C", "citedby": "0"}, {"bib": {"title": "Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:za7pDTvVV8kC", "citedby": "0"}, {"bib": {"title": "Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS).", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:MDX3w3dAD3YC", "citedby": "0"}, {"bib": {"title": "Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors.", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8VtEwCQfWZkC", "citedby": "0"}, {"bib": {"title": "Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials.", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:R22Rs3tN8aoC", "citedby": "0"}, {"bib": {"title": "IN VITRO GLUCURONIDATION OF APREPITANT: A POTENTIAL INHIBITOR OF INTESTINAL UGT2B7.: PI-45", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BJtnxTr0fRcC", "citedby": "0"}, {"bib": {"title": "VATALANIB POPULATION PHARMACOKINETICS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: CALGB 10105 (ALLIANCE).: PII-84", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M_lZXyI38BkC", "citedby": "0"}, {"bib": {"title": "ASSESSMENT OF THE PHARMACOGENOMIC EVIDENCE OF CARDIOVASCULAR DRUGS FOR CLINICAL IMPLEMENTATION.: PII-40", "year": "2013"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9shLKfS_uJEC", "citedby": "0"}, {"bib": {"title": "A STUDY OF FINANCIAL BURDENS (FB), QUALITY OF LIFE AND PSYCHOLOGICAL DISTRESS AMONG ADVANCED CANCER PATIENTS (ACP) IN PHASE I TRIALS: 284", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u0Mu_IsstPMC", "citedby": "0"}, {"bib": {"title": "238 Understanding and managing intraindividual pharmacokinetic variability", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wUn16MOA3RoC", "citedby": "0"}, {"bib": {"title": "Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study.", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Kqc1aDSOPooC", "citedby": "0"}, {"bib": {"title": "Evaluation of utility of pharmacokinetic studies in phase I combination trials.", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BAanoTsO0WEC", "citedby": "0"}, {"bib": {"title": "Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ndLnGcHYRF0C", "citedby": "0"}, {"bib": {"title": "The Virtue of Low-Flow Toilets Reply", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8uzoZH4hB9AC", "citedby": "0"}, {"bib": {"title": "Reply to MN Needle", "year": "2012"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:gV6rEsy15s0C", "citedby": "0"}, {"bib": {"title": "Psychosocial Issues and Decision Making in Clinical Trials: Associations between Symptom Burdens and Expectations of Benefit for Advanced Cancer Patients and Spousal Caregivers \u2026", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:j8pvxH-kN2QC", "citedby": "0"}, {"bib": {"title": "PP 38 A fully automated molecular diagnostic system capable of point-of-care for personalized cancer treatment", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:q0uBw5dMOAkC", "citedby": "0"}, {"bib": {"title": "1427 POSTER Fully Automated Molecular Diagnostic System for Personalized Therapy on Colorectal Cancer", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BOlwja0KXvYC", "citedby": "0"}, {"bib": {"title": "Associations between symptom burdens (SB) and expectations of benefit (EB) for advanced cancer patients (ACP) and spousal caregivers (SC) participating in phase I trials.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:S2WlVNSe3u4C", "citedby": "0"}, {"bib": {"title": "A feasibility study of a fully automated molecular diagnostic system for mutation analysis of colorectal cancer.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:natZJ_-F0IUC", "citedby": "0"}, {"bib": {"title": "Current dilemmas in carboplatin dosing.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oTdOBqtIf_kC", "citedby": "0"}, {"bib": {"title": "Merrill Jon Egorin, MD, 1948\u20132010", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uUvzmPk0f8oC", "citedby": "0"}, {"bib": {"title": "High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cOfwuRB03ygC", "citedby": "0"}, {"bib": {"title": "Irinotecan", "year": "2011"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yeL6HyUMUGUC", "citedby": "0"}, {"bib": {"title": "Expectations of benefit and symptom burdens among advanced cancer patients (ACP) and spousal caregivers during the course of phase I trials.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pUxgyZctzPYC", "citedby": "0"}, {"bib": {"title": "Communication of the essential elements of informed consent (IC) for research: A RIAS analysis of phase I clinical trial encounters.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:d4tt_xEv1X8C", "citedby": "0"}, {"bib": {"title": "Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9NZAP19TdFAC", "citedby": "0"}, {"bib": {"title": "An intronic polymorphism determines TGF-alpha expression and is associated with cellular resistance to erlotinib", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jlhcAiayVhoC", "citedby": "0"}, {"bib": {"title": "Comparing Visual, Morphometric and Biochemical Methods for Estimating Liver Fat Content", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pRWBApOjXDcC", "citedby": "0"}, {"bib": {"title": "UGT1A1* 28 POLYMORPHISM CORRELATES WITH SN-38 GLUCURONIDATION ACTIVITY INHIBITED BY ERLOTINIB.: PIII-43", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Tfl4UtY-dJUC", "citedby": "0"}, {"bib": {"title": "INCONSISTENT LABELING OF FOOD EFFECT FOR ORAL AGENTS WITHIN FDA: DIFFERENCES BETWEEN ONCOLOGY AND NON-ONCOLOGY PRODUCTS.: PIII-20", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:7VEv-pLvLSsC", "citedby": "0"}, {"bib": {"title": "INTERRACIAL DIFFERENCES IN REGULATION OF HEPATIC UDP-GLUCURONOSYLTRANSFERASE 2B BY TRANSCRIPTION FACTORS.: PIII-42", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:W2uZP3ddy8sC", "citedby": "0"}, {"bib": {"title": "Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology Michael L. Maitland Christine Hudoba 4 Kelly L. Snider 5", "year": "2010"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tgTmbKTkO1IC", "citedby": "0"}, {"bib": {"title": "Conflict of Interest Policies", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lbI08cpqPnQC", "citedby": "0"}, {"bib": {"title": "in Cancer Treatment", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JdL-Xu2nR38C", "citedby": "0"}, {"bib": {"title": "Cognitive function (CF) and prognostic information understanding in advanced cancer patients (ACP)", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nWoA1JPTheMC", "citedby": "0"}, {"bib": {"title": "Development of combination chemotherapy regimens: What is the yield of published phase II trials?", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PuOEWVtPfzwC", "citedby": "0"}, {"bib": {"title": "Effects of vascular endothelial growth factor (VEGF) signaling inhibition on human erythropoiesis", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:pYKElYtJMmwC", "citedby": "0"}, {"bib": {"title": "ASCPT NewS", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:s1ouQE5r0WUC", "citedby": "0"}, {"bib": {"title": "Abstract# 3928: EGFR haplotypes confer risk for tyrosine kinase domain mutations in non-small cell lung cancer", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KTwcwpFFj4wC", "citedby": "0"}, {"bib": {"title": "Abstract# LB-135: Grapefruit juice significantly increases bioavailability of weekly rapamycin (sirolimus)-evidence of safety and activity in a phase 1 study", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:In6cVmBjs0IC", "citedby": "0"}, {"bib": {"title": "Abstract# 2907: Interactions between MDM2 copy number, SNP309 and P53 mutation status, and their impact on drug response in cancer cells", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AZju0d2GQJ0C", "citedby": "0"}, {"bib": {"title": "INHIBITION OF ERLOTINIB AGAINST UDP-GLUCURONOSYLTRANSFERASE 1A1", "year": "2009"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rLGzs9wiiwIC", "citedby": "0"}, {"bib": {"title": "PMC1368173.", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:v6PuF9mNY3oC", "citedby": "0"}, {"bib": {"title": "THE ROLE OF PHARMACOGENETICS IN PREDICTING AND MANAGING DRUG TOXICITY", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sgsej9ZJWHMC", "citedby": "0"}, {"bib": {"title": "INFORMED CONSENT (IC), COGNITIVE PERFORMANCE (CP), AGE, AND PSYCHOLOGICAL DISTRESS (PD), AMONG ADVANCED CANCER PATIENTS (ACP) ENROLLING IN PHASE I TRIALS", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vnF2_uLGgtgC", "citedby": "0"}, {"bib": {"title": "Genetic dissection of the mTOR pathway in the HapMap lymphoblastoid cell lines", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:J3LtWjKFLicC", "citedby": "0"}, {"bib": {"title": "Searching for genes with (TG/CA) n dinucleotide repeats in intron 1 regions", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:g8uWPOAv7ggC", "citedby": "0"}, {"bib": {"title": "Reply to the Letter to the Editor from Banerji et al", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:T8_be82Iz5gC", "citedby": "0"}, {"bib": {"title": "Biomarkers in early clinical trials: The committed and the skeptics-Response", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:U0iAMwwPxtsC", "citedby": "0"}, {"bib": {"title": "Response: Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non\u2013Small Cell Lung Cancer", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:I8rxH6phXEkC", "citedby": "0"}, {"bib": {"title": "CO-REGULATION OF HEPATIC UDP-GLUCURONOSYLTRANSFERASE 1As BY TRANSCRIPTION FACTORS.: PIII-27", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:B2rIPIGFPLEC", "citedby": "0"}, {"bib": {"title": "Role of the mapk cascade in a rodent model of pulmonary hypertension", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XAp-VaTZjjwC", "citedby": "0"}, {"bib": {"title": "Co-regulation of hepatic UDP-glucuronosyltransferase 1 as by transcription factors.", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DXE8ND7PrJAC", "citedby": "0"}, {"bib": {"title": "Cognitive performance (cp), informed consent (ic), and age among advanced cancer patients (acp)", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vxA22ZmNLkoC", "citedby": "0"}, {"bib": {"title": "IRINOGENETICS", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:e84hm74t-eoC", "citedby": "0"}, {"bib": {"title": "438 POSTER Pharmacodynamics (PD) of GRN163L in a Phase I study in refractory, solid tumors", "year": "2008"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KS-xo-ZNxMsC", "citedby": "0"}, {"bib": {"title": "Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties (vol 13, pg 2400, 2007)", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wlzmIqt2EaEC", "citedby": "0"}, {"bib": {"title": "Serum glucose measurements as a pharmacodynamic biomarker for mTOR inhibition", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WIXB4To3Tx4C", "citedby": "0"}, {"bib": {"title": "Clinical investigation of sorafenib pharmacokinetics and pharmacodynamic biomarkers", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:XDrR66g3YHsC", "citedby": "0"}, {"bib": {"title": "PMC4465230.", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:x21FZCSn4ZoC", "citedby": "0"}, {"bib": {"title": "Predictive markers for response to EGFR inhibitors in the NCI60 cell lines", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ifOnle78iJkC", "citedby": "0"}, {"bib": {"title": "HEPATOCYTE NUCLEAR FACTOR-1 ALPHA IS ASSOCIATED WITH UGT1A1, UGT1A9 AND UGT2B7 mRNA EXPRESSION IN HUMAN LIVER.: PII-41", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wuD5JclIwkYC", "citedby": "0"}, {"bib": {"title": "96 DYAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING PHARMACODYNAMIC STUDY OF SORAFENIB IN METASTATIC RENAL CELL CARCINOMA: PRELIMINARY RESULTS OF A RANDOMIZED, PHASE II TRIAL.", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DQNrXyjhriIC", "citedby": "0"}, {"bib": {"title": "76 ATTENUATION OF A RODENT MODEL OF PULMONARY HYPERTENSION: A NOVEL ROLE FOR SORAFENIB, A MULTIKINASE INHIBITOR.", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oqD4_j7ulsYC", "citedby": "0"}, {"bib": {"title": "ASSOCIATION OF COMMON POLYMORPHISMS IN UGT2B15 AND UGT2B17 WITH INTERINDIVIDUAL VARIABILITY IN SUBSTRATE GLUCURONIDATION.: PII-34", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cNe27ouKFcQC", "citedby": "0"}, {"bib": {"title": "THE UGT1A9 INTRONIC I399 POLYMORPHISM IS NOT ASSOCIATED WITH UGT1A9 ACTIVITY OR mRNA EXPRES-SION.: PIII-7", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WwIwg2wKZ0QC", "citedby": "0"}, {"bib": {"title": "Trends in the Use and Role of Biomarkers in Phase I Oncology Trials. Commentary", "year": "2007"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3vbIHxFL9FgC", "citedby": "0"}, {"bib": {"title": "Selective Kinase Inhibition Attenuates Rodent Pulmonary Arterial Hypertension (PAH)", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qsWQJNntlusC", "citedby": "0"}, {"bib": {"title": "Problems With the Randomized Discontinuation Design", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5F1dSjz1ScoC", "citedby": "0"}, {"bib": {"title": "Stepwise development of biomarkers for angiogenic activity with standardized assays for circulating molecules in human subjects", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AFXcoJnoRH0C", "citedby": "0"}, {"bib": {"title": "Case History: The First Drug-Specific FDA-Approved Pharmacogenetic Test: UGT1A1 Genotyping for Irinotecan", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Y9VhQm-5nPIC", "citedby": "0"}, {"bib": {"title": "Support for oral kinase inhibitor therapy in cytokine-refractory metastatic RCC", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:LWqeokA2EBkC", "citedby": "0"}, {"bib": {"title": "Patients involved in clinical research are more concerned about intrinsic and traditional research (\" publish or perish\") conflicts of interests (COI) than potential financial \u2026", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:iKswqCX-FLkC", "citedby": "0"}, {"bib": {"title": "Patients involved in clinical research are more concerned about intrinsic and traditional research (\u201cpublish or perish\u201d) conflicts of interests (COI) than potential financial \u2026", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5LPo_wSKItgC", "citedby": "0"}, {"bib": {"title": "Pharmacogenetic pathway analysis of irinotecan", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Vno172sVVMwC", "citedby": "0"}, {"bib": {"title": "Genome-wide screen for DNA copy number changes correlated with cytotoxicity to EGFR-targeted anticancer agents", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KI9T_ytC6pkC", "citedby": "0"}, {"bib": {"title": "Sensitivity and resistance of EGFR inhibitors in the NCI60 cell lines: Effects of both germline polymorphisms and somatic mutations", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:m92CDrhVnKEC", "citedby": "0"}, {"bib": {"title": "Selective killing of cancer cells by leaf extract of Ashwagandha: Identification of a tumor-inhibitory factor and the first molecular insights to its effect.", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:h9G0ZmjYpDoC", "citedby": "0"}, {"bib": {"title": "Perineural invasion is not prognostic in prostate cancer treated with brachytherapy", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:IHkkN1K1AlAC", "citedby": "0"}, {"bib": {"title": "Original Reports-PHASE I AND CLINICAL PHARMACOLOGY-Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B \u2026", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Gb6Hms-Uo9kC", "citedby": "0"}, {"bib": {"title": "33 INVITED Combination of tyrosine kinase inhibitors, or monoclonal antibodies, with radiotherapy and chemotherapy", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:i91s68tWr-MC", "citedby": "0"}, {"bib": {"title": "230 INVITED From biomarkers to clinical utility", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Y0-TYkg6YM4C", "citedby": "0"}, {"bib": {"title": "Original Reports-GENITOURINARY CANCER-Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma", "year": "2006"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NMlhSUseqAsC", "citedby": "0"}, {"bib": {"title": "Randomized discontinuation trials.", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:AFmTUeZ1pmEC", "citedby": "0"}, {"bib": {"title": "Pharmacogenomrics of deferiprone metabolism.", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:0ngZmJvimKcC", "citedby": "0"}, {"bib": {"title": "Analysis of phase II studies for the year 2002: Design, conclusions and impact factors of oncology vs. non-oncology trials", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PVqtIyvKoSUC", "citedby": "0"}, {"bib": {"title": "Determination of response to taxol/carboplatin in ovarian cancer patients", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ul_CLA4dPeMC", "citedby": "0"}, {"bib": {"title": "Genetic determinants of UGT1A1 inducibility", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1EqfMoDn7-AC", "citedby": "0"}, {"bib": {"title": "Role of HNF\u20101\u03b1 in the regulation of UGT1A1, UGT1A9 and UGT2B7 MRNA expression", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ukw-9cB-YDkC", "citedby": "0"}, {"bib": {"title": "Inhibition of SN\u201038 glucuronidation by ketoconazole", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SpPTWFSNUtQC", "citedby": "0"}, {"bib": {"title": "UGT1A1 and UGT1A9 variants affect thyroxine glucuronidation in human livers", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:sbeIDTyQOFgC", "citedby": "0"}, {"bib": {"title": "In vitro glucuronidation of prednisone", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:n3vGvpFsckwC", "citedby": "0"}, {"bib": {"title": "PII-37", "year": "2005"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rzmi0EmCOGEC", "citedby": "0"}, {"bib": {"title": "Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WWeOtg8bX_EC", "citedby": "0"}, {"bib": {"title": "EFFECTS OF KETOCONAZOLE ON SN-38 GLUCURONIDATION BY UDP-GLUCURONOSYLTRANSFERASE (UGT) 1A ENZYMES", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Pqt4MY__2vwC", "citedby": "0"}, {"bib": {"title": "Old principles in new clothes", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yJjnfzR0HrkC", "citedby": "0"}, {"bib": {"title": "Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan: 2085", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aNch6Af-aFkC", "citedby": "0"}, {"bib": {"title": "A dose-escalation study of the quinoxaline antitumor agent R (+) XK469 (XK) in patients with refractory solid tumors: 2021", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:JTtNqH-x4gYC", "citedby": "0"}, {"bib": {"title": "Patients (pts) understanding of phase II trial designs and informed consent (IC)", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:a2necdfpwlEC", "citedby": "0"}, {"bib": {"title": "Two SNPs in the epidermal growth factor receptor (EGFR) gene promoter are associated with gene expression in vitro.", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rCNdntzdTkkC", "citedby": "0"}, {"bib": {"title": "Role of CYP3A4 and CYP2B6 in the in vitro N\u2010demethylation of meperidine", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6VlyvFCUEfcC", "citedby": "0"}, {"bib": {"title": "Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KIRwYnRZzWQC", "citedby": "0"}, {"bib": {"title": "Original Reports-PHASE I AND CLINICAL PHARMACOLOGY-Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:q1zXlPLtbUIC", "citedby": "0"}, {"bib": {"title": "Experimental Therapeutics, Molecular Targets, and Chemical Biology-Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity.", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:tBlTYpvFGQIC", "citedby": "0"}, {"bib": {"title": "390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis", "year": "2004"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mWEH9CqjF64C", "citedby": "0"}, {"bib": {"title": "O-142 Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin\u2122)", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cSdaV2aYdYsC", "citedby": "0"}, {"bib": {"title": "THE UNIVERSITY OF CHICAGO THE DIVISION OF THE BIOLOGICAL SCIENCES And THE PRITZKER SCHOOL OF MEDICINE", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Nufq_to8ts0C", "citedby": "0"}, {"bib": {"title": "A pharmacogenetic study on UDP\u2010glucuronosyltransferase 2B7 in human livers", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:uAPFzskPt0AC", "citedby": "0"}, {"bib": {"title": "CYP3A4, CYP3A5 and CYP2C9 Are Responsible For The N\u2010Demethylation of Meperidine to Normeperidine in Vitro", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bVQMTfhMCi4C", "citedby": "0"}, {"bib": {"title": "Use of CPT\u201011 as an in vitro phenotypic probe for CYP3A4/CYP3A5 activity", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hNSvKAmkeYkC", "citedby": "0"}, {"bib": {"title": "Pharmacogenetics of anticancer agents", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:WzTVkKNmPSkC", "citedby": "0"}, {"bib": {"title": "Molecular Oncology, Markers, Clinical Correlates-Interethnic Difference in the Allelic Distribution of Human Epidermal Growth Factor Receptor Intron 1 Polymorphism.", "year": "2003"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NtCmTCuxid4C", "citedby": "0"}, {"bib": {"title": "Troxacitabine in patients with refractory leukemia.", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:xGWFX6Gbr9MC", "citedby": "0"}, {"bib": {"title": "Genetic mutations in human UGT1A1 enhancer and SN-38 glucuronidation.", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:3MwzVuqRcA0C", "citedby": "0"}, {"bib": {"title": "Modulation of carboxyamido-triazole (C) pharmacokinetics by ketoconazole (K) in cancer patients.", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EaFouW7jFu4C", "citedby": "0"}, {"bib": {"title": "Interindividual and interfamilial variability in susceptibility to camptothecin.", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:yY3RG6sOEgwC", "citedby": "0"}, {"bib": {"title": "A multicenter study of inhaled doxorubicin (Resmycin (TM)) in adults with advanced solid tumors affecting the lungs", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cB__R-XWw9UC", "citedby": "0"}, {"bib": {"title": "Estudio de fase I de doxorrubicina lipos\u00f3mica pegilada, paclitaxel y cisplatino en pacientes con tumores s\u00f3lidos avanzados", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rqnDXT1GswoC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS-Quality of Life and Supportive Care-Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:orDZ08hpP44C", "citedby": "0"}, {"bib": {"title": "Genitourinary Cancer-Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of \u2026", "year": "2002"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SIv7DqKytYAC", "citedby": "0"}, {"bib": {"title": "Feasibility of the randomized discontinuation clinical trial design for assessing cytostatic drug activity.", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:DIubQTN3OvUC", "citedby": "0"}, {"bib": {"title": "PI-40 CORRELATION BETWEEN EPIRUBICIN AND MORPHINE GLUCURONIDATION", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:CMvovTBb2okC", "citedby": "0"}, {"bib": {"title": "Pharmacogenomic expression profiling of psoriasis", "year": "2001"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:8gBurD7jEYQC", "citedby": "0"}, {"bib": {"title": "Determination of the optimal modulatory dose of O-6-benzylguanine in patients with surgically resectable tumor.", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wSy_KLzO7YEC", "citedby": "0"}, {"bib": {"title": "A phase I study of escalating doses of docetaxel (TXT) with G-CSF support in patients with advanced malignancies", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:QoJ_w57xiyAC", "citedby": "0"}, {"bib": {"title": "Epirubicin is glucuronidated by UGT2B7.", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4QKQTXcH0q8C", "citedby": "0"}, {"bib": {"title": "Development and validation of a model for the disposition of irinotecan (CPT11) and its metabolites over a wide dose range.", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:FsLZdJ3BAzkC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS-Phase I and Pharmacokinetics-Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565", "year": "2000"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Zh0EY9V9P6UC", "citedby": "0"}, {"bib": {"title": "Development of an assay to detect farnesyl protein transferase inhibitor-Mediated Ras retargeting in leukemic cells.", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:idthP5jqfYAC", "citedby": "0"}, {"bib": {"title": "Hope and awareness of prognosis in advanced cancer patients (pts).", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Azgs6IHzeyYC", "citedby": "0"}, {"bib": {"title": "Possible interactions between dietary antioxidants and chemotherapy-The Labriola/Livingston article reviewed", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RgznTc0nqo4C", "citedby": "0"}, {"bib": {"title": "A Pharmacokinetic (PK) Model for Irinotecan and Its Metabolites in Cancer Patients", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:rbGdIwl2e6cC", "citedby": "0"}, {"bib": {"title": "Characterization of the human dihydropyrimidine dehydrogenase gene.", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:o-PowTg_VKEC", "citedby": "0"}, {"bib": {"title": "Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cww_0JKUTDwC", "citedby": "0"}, {"bib": {"title": "The Article Reviewed-Possible Interactions Between Dietary Antioxidants and Chemotherapy", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:NU-BerS4NX4C", "citedby": "0"}, {"bib": {"title": "5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy: New Drugs", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:hefNtdE4IMkC", "citedby": "0"}, {"bib": {"title": "PHARMACOGENETICS AND GENOMICS-Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 \u2026", "year": "1999"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:1r-w4gtu6w8C", "citedby": "0"}, {"bib": {"title": "A flat dose for all adult [sic] patients-In reply", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:G36d5HCDkJYC", "citedby": "0"}, {"bib": {"title": "The relationship between preferences for medical decision control and the outcome of informed consent among advanced cancer patients receiving experimental therapies.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:R-LXmdHK_14C", "citedby": "0"}, {"bib": {"title": "Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes.", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ON9TkA72AHEC", "citedby": "0"}, {"bib": {"title": "Camptothecin Analo gues: Topotecan and Irinotecan", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:mgoTDWlsYNUC", "citedby": "0"}, {"bib": {"title": "A FLAT DOSE FOR ALL ADULT SIC PATIENTS. AUTHOR'S REPLY", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:_IsBomjs8bsC", "citedby": "0"}, {"bib": {"title": "Phase I clinical and pharmacologic study of O^ 6 benzylguanine plus carmustine in patients with advanced cancer", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M0j1y4EgrScC", "citedby": "0"}, {"bib": {"title": "Phase I and Pharmacokinetic Trial of Paclitaxel in Patients With Hepatic Dysfunction: Cancer and Leukemia Group B", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VnuxuLaQPLMC", "citedby": "0"}, {"bib": {"title": "Pharmacokinetics and Pharmacodynamic Studies-Phase I and Pharmacologic Study of Continuous Infusion Topotecan in Combination With Cisplatin in Patients With Advanced Cancer: A \u2026", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:j5aT6aphRxQC", "citedby": "0"}, {"bib": {"title": "A phase 1 study of raltitrexed (Tomudex (R)) and paclitaxel", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:4n0clTBhZ78C", "citedby": "0"}, {"bib": {"title": "Phase I study of the dihydropyrimidine dehydrogenase (DPD) inhibitor eniluracil (GW776C85) and oral 5-FU with concomitant radiotherapy (XRT) for recurrent or advanced head and \u2026", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:h168fVGZblEC", "citedby": "0"}, {"bib": {"title": "SPECIAL DEPARTMENTS-In Reply-A Flat Dose for All Adult (sic) Patients", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YPNY0knpFBYC", "citedby": "0"}, {"bib": {"title": "A phase I study of oral uracil/ftorofur plus leucovorin and oral JM-216 each given over 14 days every 28 days", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:xm0LlTxljI0C", "citedby": "0"}, {"bib": {"title": "General overview: What can we learn from the drug development of non-cancer drugs?", "year": "1998"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lg2tdxc6qMwC", "citedby": "0"}, {"bib": {"title": "DISPOSITION OF LOSOXANTRONE AFTER INTRAVENOUS ADMINISTRATION OF 14C-LOSOXANTRONE TO CANCER PATIENTS: 44", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:I9gX6wnfuA8C", "citedby": "0"}, {"bib": {"title": "166 A phase II study of CI-980 in advanced non small cell lung cancer (NSCLC)", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:u3T1itk59dMC", "citedby": "0"}, {"bib": {"title": "5 A phase II study of 9-aminocamptothecin (9-AC) in patients (pts) with non small cell lung cancer (NSCLC)", "year": "1997"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:I858iXPj1OkC", "citedby": "0"}, {"bib": {"title": "Data modifications to phase I study of suramin.", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aDl3D7KC1E4C", "citedby": "0"}, {"bib": {"title": "Detection of IgH and IgL rearrangements in intermediate and high grade B-cell non Hodgkin's lymphomas", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:V_vSwabWVtYC", "citedby": "0"}, {"bib": {"title": "Ligand toxin fusion proteins are a new class of therapies with antitumor activity in non-Hodgkin's lymphoma", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:nPTYJWkExTIC", "citedby": "0"}, {"bib": {"title": "Fostriecin nephrotoxicity: an in vitro assessment", "year": "1996"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Vztgr1qGG8IC", "citedby": "0"}, {"bib": {"title": "PHASE-I CLINICAL-EVALUATION OF OLTIPRAZ (OLT) AS A CHEMOPREVENTIVE AGENT", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:cBPnxVikjH8C", "citedby": "0"}, {"bib": {"title": "Clinical case", "year": "1995"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:R6EwkKsDylYC", "citedby": "0"}, {"bib": {"title": "PHASE-I TRIALS-EXPECTATIONS OF CANCER-PATIENTS AND THEIR ONCOLOGISTS", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:VRfTbSk87rEC", "citedby": "0"}, {"bib": {"title": "18 Pharmacodynamics of Antineoplastic Agents", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kUhpeDhEZMUC", "citedby": "0"}, {"bib": {"title": "A PHASE-I STUDY OF SURAMIN (SUR) IN PATIENTS WITH ADVANCED CANCER (CA)", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:BW2nPTmhBn4C", "citedby": "0"}, {"bib": {"title": "PHASE-I TRIAL OF THIOTEPA, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND PREDNISONE OR PENTOXIFYLLINE IN PATIENTS WITH REFRACTORY SOLID TUMORS", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:M0leSnx2MbUC", "citedby": "0"}, {"bib": {"title": "Phase I study of escalating does of carboplatin.", "year": "1994"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qmtmRrLr0tkC", "citedby": "0"}, {"bib": {"title": "THE VALUE OF SUPPORTIVE CARE AND PREVENTION OF SIDE-EFFECTS TO THE PATIENT", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:lK9BDNCuzFgC", "citedby": "0"}, {"bib": {"title": "INCREASED INCIDENCE OF 2ND NEOPLASMS IN PATIENTS WITH HAIRY-CELL LEUKEMIA (HCL) TREATED WITH INTERFERON", "year": "1993"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:iyewoVqAXLQC", "citedby": "0"}, {"bib": {"title": "SERUM INTERLEUKIN-2 RECEPTOR AS INDEX OF TUMOR BURDEN IN HAIRY-CELL LEUKEMIA-RESPONSE", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:as0KMg8qHbkC", "citedby": "0"}, {"bib": {"title": "QUANTITATIVE ASSESSMENT OF ACCUMULATING DATA IN PHASE I CANCER CLINICAL-TRIALS", "year": "1991"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:EBV337fEn3EC", "citedby": "0"}, {"bib": {"title": "PHASE-I STUDY OF HIGH-DOSE AMONAFIDE WITH AUTOLOGOUS BONE-MARROW RESCUE (ABMR)", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:kO05sadLmrgC", "citedby": "0"}, {"bib": {"title": "Duration of response after interferon treatment of hairy cell leukemia.", "year": "1990"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:9LpHyFPp1DQC", "citedby": "0"}, {"bib": {"title": "HAIRY-CELL LEUKEMIA-REPLY", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wGzT3bKASkAC", "citedby": "0"}, {"bib": {"title": "QUANTIFICATION OF MITOXANTRONE IN LIVER-TISSUE FOLLOWING INTRAPERITONEAL AND INTRAVENOUS ADMINISTRATION IN PIGS", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Ej9njvOgR2oC", "citedby": "0"}, {"bib": {"title": "COMPARATIVE CELLULAR PHARMACOKINETICS (CPK) OF THE VINCA ALKALOIDS", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:oldoQiaHq2UC", "citedby": "0"}, {"bib": {"title": "A PREDICTIVE MODEL FOR VINBLASTINE PHARMACO-KINETICS USING LIMITED SAMPLING", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:RfUwGJFMQ-0C", "citedby": "0"}, {"bib": {"title": "PHARMACOKINETICS (PK) OF THIOTEPA (TT) FOLLOWING HIGH-DOSE ADMINISTRATION", "year": "1987"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ymY9cBF3mdcC", "citedby": "0"}, {"bib": {"title": "COMPLICATIONS OF AN IMPLANTED PUMPING SYSTEM FOR SYSTEMIC CHEMOTHERAPY", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:bXQfdp6S9ecC", "citedby": "0"}, {"bib": {"title": "HUMAN-PLASMA PHARMACOKINETICS OF THIOTEPA (TT) FOLLOWING HIGH-DOSE ADMINISTRATION", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:wyM6WWKXmoIC", "citedby": "0"}, {"bib": {"title": "Phase I Clinical and Pharmacological Study of Thymidine (NSC 21548) and cis-Diamminedichloroplatinum (II) in Patients with Advanced Cancer1", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KqnX2w3egDsC", "citedby": "0"}, {"bib": {"title": "FLOW CYTOMETRIC EVIDENCE FOR INCREASING NATURAL-KILLER (NK) CELL-ACTIVITY IN PATIENTS WITH HAIRY-CELL LEUKEMIA (HCL) TREATED WITH ALPHA-2INTERFERON (IFN)", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:jtI9f0ekYq0C", "citedby": "0"}, {"bib": {"title": "A PHASE-I-II STUDY OF BIALKYLATOR CHEMOTHERAPY (BACT) WITH HIGH-DOSE THIOTEPA (TT) AND CYTOXAN AND AUTOLOGOUS BONE-MARROW REINFUSION IN PATIENTS WITH REFRACTORY LYMPHOMA AND \u2026", "year": "1986"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:YB4bud6kWLwC", "citedby": "0"}, {"bib": {"title": "PROLONGED INFUSION OF VINBLASTINE WITH ANALYSIS OF STEADY-STATE DRUG LEVELS", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:ShjGdcaqzI0C", "citedby": "0"}, {"bib": {"title": "SEVERE TOXICITY DURING A PHASE-I TRIAL OF VINBLASTINE AND RECOMBINANT GAMMA-INTERFERON", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:w2UhwfzvF0QC", "citedby": "0"}, {"bib": {"title": "EFFECTIVE THERAPY FOR ADVANCED HAIRY-CELL LEUKEMIA WITH ALPHA-2-INTERFERON-AN UPDATE", "year": "1985"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Og1tA8FjbJAC", "citedby": "0"}, {"bib": {"title": "RAPID RESPONSES IN ADVANCED HAIRY-CELL LEUKEMIA (HCL) WITH RECOMBINANT ALPHA-2-INTERFERON (IFN)", "year": "1984"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Vr2j17o0sqMC", "citedby": "0"}, {"bib": {"title": "List of contents", "year": "1966"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:aEW5N-EHWIMC", "citedby": "0"}, {"bib": {"title": "Combined sequential approach in locally advanced breast cancer"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:svGagg1hbZMC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:fF_gHTpLxhAC", "citedby": "0"}, {"bib": {"title": "A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:6pF0wJmtdfAC", "citedby": "0"}, {"bib": {"title": "THE UNIVERSITY OF CHICAGO THE DIVISION OF THE BIOLOGIAL SCIENCES And THE PRITZKER SCHOOL OF MEDICINE"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:KqW5X_olkfQC", "citedby": "0"}, {"bib": {"title": "Limited Sampling Model for Area under the Concentration Time Curve of Total Topotecan"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:5VjbC5aozO0C", "citedby": "0"}, {"bib": {"title": "IL, USA."}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:feST4K8J0scC", "citedby": "0"}, {"bib": {"title": "Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients \u2026"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vjZqxyZ7hS4C", "citedby": "0"}, {"bib": {"title": "DATA and SAFETY MONITORING GUIDELINES For CLINICAL TRIALS"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:N6_Y7JlWxwsC", "citedby": "0"}, {"bib": {"title": "HYPERFRACTIONATED RADIOTHERAPY WITH CONCOMITANT FLUOROURACIL AND HYDROXYUREA FOR INTERMEDIATE STAGE CANCER OF THE HEAD AND NECK"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qPeb-qHga9sC", "citedby": "0"}, {"bib": {"title": "Prescribing Oral Anticancer Agents: Food-Induced Injury Is Preventable"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:Oo1CbQkBAzEC", "citedby": "0"}, {"bib": {"title": "CANCER AND LEUKEMIA GROUP B CALGB 30607 RANDOMIZED, PHASE III, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF SUNITINIB (NSC# 736511, IND# 74019) AS MAINTENANCE THERAPY IN NON \u2026"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:qCpRzq7zkD8C", "citedby": "0"}, {"bib": {"title": "CANCER AND LEUKEMIA GROUP B CALGB 40503/CTSU 40503 ENDOCRINE THERAPY WITH OR WITHOUT ANTI-VEGF THERAPY: A RANDOMIZED, PHASE III TRIAL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE \u2026"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:SrKkpNFED5gC", "citedby": "0"}, {"bib": {"title": "IRB Number 8626"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:GYcXSSpN504C", "citedby": "0"}, {"bib": {"title": "CANCER AND LEUKEMIA GROUP B CALGB 90802"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:g_UdREhPGEoC", "citedby": "0"}, {"bib": {"title": "CANCER AND LEUKEMIA GROUP B CALGB 100103/BMT CTN 0502 AP HASE II STUDY OF ALLOGENEIC TRANSPLANT FOR OLDER PATIENTS WITH AML IN FIRST MORPHOLOGIC COMPLETE REMISSION USING A NON \u2026"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:vVJNg6_NJEsC", "citedby": "0"}, {"bib": {"title": "Speaker Contact Information"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:TGkaJS32XoUC", "citedby": "0"}, {"bib": {"title": "Activation Date: 02/15/10 Includes Update# 2 CALGB 80802"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:eH23hyXCXa4C", "citedby": "0"}, {"bib": {"title": "Our thanks to all those who have helped with this issue of Future Oncology. Listed below are authors, referees and others who have kindly given their time, effort and expertise \u2026"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:PlWzFYVEG4EC", "citedby": "0"}, {"bib": {"title": "Part A: Pharmacogenomic Determinants of Response and Toxicity in CALGB 40601 Pharmacogenomic Investigators: Deanna Kroetz, Ph. D. University of California, San Francisco E \u2026"}, "source": "citations", "id_citations": "9Q6X14MAAAAJ:N4u4nq0IxgcC", "citedby": "0"}]}